<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":7714,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/d7074db4db9ad4e305df80d1335feb34'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/d7074db4db9ad4e305df80d1335feb34'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court Opinion'>
R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court Opinion</div>
<div class='docId'>X1I51L0003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>R.J. Reynolds Tobacco Co. v. FDA</div>
<div class='displayCitation'>2012 BL 217700</div>
<div class='displayCitation'>402 U.S. App. D.C. 438</div>
<div class='displayCitation'>696 F.3d 1205</div>
<div class='displayCitation'>wkfdccase:26297168</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I51L0003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="R.J. Reynolds Tobacco Co. v. FDA" />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1I51L0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I51L0003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I51L0003" /><input id="title" name="title" type="hidden" value="R.J. Reynolds Tobacco Co. v. FDA, 696 F.3d 1205, 402 U.S. App. D.C. 438 (D.C. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="d7074db4db9ad4e305df80d1335feb34" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I51L0003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Fd%37%30%37%34db%34db%39ad%34e%33%30%35df%38%30d%31%33%33%35feb%33%34%2Fdocument%2FX%31I%35%31L%30%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/bcite/X1I51L0003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/bcite/X1I51L0003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/bcite/X1I51L0003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/related_content/X1I51L0003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1723411202051";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,SecondaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">696 F.3d 1205</div>
<div class="cite" data-cite-type="SecondaryFederalReporter">402 U.S. App. D.C. 438</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 11-5332, 12-5063.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 217700</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S. App. D.C. </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, District of Columbia Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
R.J. REYNOLDS TOBACCO COMPANY, et al., Appellees v. FOOD &amp; DRUG
ADMINISTRATION, et al., Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 11-5332, 12-5063.
</center></p>
<p><center>
Argued April 10, 2012.
</center></p>
<p><center>
Decided August 24, 2012.
<span CLASS="page_no" data-cite="402 us appeals dc 440" data-cite-type="SecondaryFederalReporter" data-cite-pageno="440" data-primary-citation="402 U.S. App. D.C. 438">[**440]</span> </center></p>
<div id="para2" printdualcolumn="true"><p>
Appeals from the United States District Court for the District of Columbia,
(No. 1:11-cv-01482).
<span CLASS="page_no" data-cite="696 f 3d 1206" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1206" data-primary-citation="696 F.3d 1205">[*1206]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before: ROGERS and BROWN, Circuit Judges, and RANDOLPH, Senior Circuit
Judge.
</p></div>
<div id="para2" printdualcolumn="true"><p>
<span CLASS="page_no" data-cite="696 f 3d 1207" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1207" data-primary-citation="696 F.3d 1205">[*1207]</span> 
Mark B. Stern, Attorney, U.S. Department of Justice, argued the cause for
appellants. With him on the briefs were Tony West, Assistant Attorney
General, Beth S. Brinkmann, Deputy Assistant Attorney General, Alisa B.
Klein, Sarong V. Damle, Daniel Tenny, and Lindsey Powell, Attorneys, William
B. Schultz, Acting General Counsel, U.S. Department of Health and Human
Services, Eric M. Blumberg, Deputy Chief Counsel, and Karen E. Schifter,
Senior Counsel. R. Craig Lawrence, Assistant U.S. Attorney, entered an
appearance.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Gregory A. Beck and Allison M. Zieve were on the brief for amici curiae
American Academy of Pediatrics, et al. in support of appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Lawrence G. Wasden, Attorney General, Office of the Attorney General for the
State of Idaho, Brett T. DeLange, Deputy Attorney General, John J. Burns,
Attorney General, Office of the Attorney General for the State of Alaska,
Tom Horns, Attorney General, Office of the Attorney General for the State of
Arizona, Dustin McDaniel, Attorney General, Office of the Attorney General
for the State of Arkansas, Kamala D. Harris, Attorney General, Office of the
Attorney General for the State of California, George Jepsen, Attorney
General, Office of the Attorney General for the State of Connecticut, Todd
S. Kim, Solicitor General, Office of the Attorney General for the District
of Columbia, David M. Louie, Attorney General, Office of the Attorney
General for the State of Hawai'i, Lisa Madigan, Attorney General, Office of
the Attorney General for the State of Illinois, Thomas J. Miller, Attorney
General, Office of the Attorney General for the State of Iowa, William J.
Schneider, Attorney General, Office of the Attorney General for the State of
Maine, Douglas F. Gansler, Attorney General, Office of the Attorney for the
State of Maryland, Jim Hood, Attorney General, Office of the Attorney
General for the State of Mississippi, Steve Bullock, Attorney General,
Office of the Attorney General for the State of Montana, Michael A. Delaney,
Attorney General, Office of the Attorney General for the State of New
Hampshire, Gary K. King, Attorney General, Office of the Attorney General
for the State of New Mexico, Michael DeWine, Attorney General, Office of the
Attorney General for the State of Ohio, Peter F. Kilmartin, Attorney
General, Office of the Attorney General for the State of Rhode Island, Marty
J. Jackley, Attorney General, Office of the Attorney General for the State
of South Dakota, Mark L. Shurtleff, Attorney General, Office of the Attorney
General for the State of Utah, <span CLASS="page_no" data-cite="2012 bl 217700 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> William H. Sorrell, Attorney General, Office
of the Attorney General for the State of Vermont, Vincent F. Frazier,
Attorney General,
<span CLASS="page_no" data-cite="402 us appeals dc 441" data-cite-type="SecondaryFederalReporter" data-cite-pageno="441" data-primary-citation="402 U.S. App. D.C. 438">[**441]</span> <span CLASS="page_no" data-cite="696 f 3d 1208" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1208" data-primary-citation="696 F.3d 1205">[*1208]</span> 
Office of the Attorney General for the Virgin Islands, Robert M. McKenna,
Attorney General, Office of the Attorney General for the State of
Washington, and Darrell V. McGraw, Jr., Attorney General, Office of the
Attorney General for the State of West Virginia, were on the brief for amici
curiae States.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Noel J. Francisco argued the cause for appellees. With him on the briefs
were Warren D. Postman, Philip J. Perry, Jonathan D. Hacker, Floyd Abrams,
Joel Kurtzberg, and Patricia A. Barald.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Bert W. Rein, John E. Barry, Robin S. Conrad, Kathryn Comerford Todd, and
Sheldon Gilbert were on the brief for amicus curiae Chamber of Commerce of
the United States of America in support of appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Daniel J. Popeo, Cory L. Andrews, and Richard A. Samp were on the brief for
amicus curiae Washington Legal Foundation.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Robert Corn-Revere and Ronald G. London were on the brief for amici curiae
Association of National Advertisers Inc., et al. in support of appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Jeffrey Light was on the brief for amicus curiae Defending Animal Rights
Today &amp; Tomorrow in support of neither party.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
BROWN, Circuit Judge:
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Opinion for the Court filed by Circuit Judge BROWN.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dissenting opinion filed by Circuit Judge ROGERS.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Family Smoking Prevention and Tobacco Control Act ("the Act"), Pub.L.
No. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USACTS%20111-31&amp;summary=yes#jcite">111-31</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=123%20Stat.%201776&amp;summary=yes#jcite">123 Stat. 1776</a> (2009), directed the Secretary of the U.S.
Department of Health and Human Services to issue regulations requiring all
cigarette packages manufactured or sold in the United States to bear one of
nine new textual warnings, as well as "color graphics depicting the negative
health consequences of smoking." <i>See </i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333(a)&amp;summary=yes#jcite">id. &sect; 201(a)</a>. Pursuant to this
authority, the Food and Drug Administration ("FDA") initiated a rulemaking
proceeding through which it selected the nine images that would accompany
the statutorily-prescribed warnings. Five tobacco companies ("the
Companies") challenged the rule, alleging that FDA's proposed graphic
warnings violated the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment. <i>See</i> Compl. at 35-36.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> The
district court granted the Companies' motion for summary judgment on
February 29, 2012.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> FDA appeals, and we affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. <b>Background</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Act gives FDA the authority to regulate the manufacture and sale of
tobacco products, including cigarettes. In addition to requiring cigarette
packages and advertisements to bear one of nine new warning statements, the
Act mandates that the new warning labels comprise the top 50 percent of the
front and rear panels of cigarette packages and 20 percent of the area of
each cigarette advertisement. Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333(a)&amp;summary=yes#jcite">&sect; 201(a)</a>, <cite>123 Stat, at 1842-45</cite>. The Act
directs the Secretary to issue final regulations
<span CLASS="page_no" data-cite="402 us appeals dc 442" data-cite-type="SecondaryFederalReporter" data-cite-pageno="442" data-primary-citation="402 U.S. App. D.C. 438">[**442]</span> <span CLASS="page_no" data-cite="696 f 3d 1209" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1209" data-primary-citation="696 F.3d 1205">[*1209]</span> 
identifying the graphic component of the warnings by June 22, 2011, and
provides that the revised health warnings will take effect by September 22,
2012. <i>See</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=15%20usc%201333&amp;summary=yes#jcite">15 U.S.C. &sect; 1333</a> note.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pursuant to the statutory directive, FDA issued a Proposed Rule seeking
comment on thirty-six potential images for the new graphic warning labels.
Required Warnings for Cigarette Packages and Advertisements, 75 Fed.Reg. 69,
524, 69, 534 (Nov. 12, 2010) (hereinafter Proposed Rule). At the outset of
the Proposed Rule, FDA asserted the government's "substantial <span CLASS="page_no" data-cite="2012 bl 217700 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> interest in
reducing the number of Americans, particularly children and adolescents, who
use cigarettes and other tobacco products in order to prevent the
life-threatening health consequences associated with tobacco use." <i></i><cite>Id. at
69</cite>, 525. In accordance with the requirements of the Act, FDA proposed a
dramatic expansion of the existing health warnings, which it justified based
on scientific literature and a "strong worldwide consensus"<a HREF="#fn300" name="fnref_fn300">[fn3]</a> regarding
the relative effectiveness of graphic warnings compared to the text-only
warnings the United States currently requires. <i><cite>Id</cite>.</i> The agency explained that
by "clearly and effectively convey[ing] the negative health consequences of
smoking," the new warnings would discourage non-smokers, particularly
minors, from "initiating cigarette use," and encourage current smokers to
quit. <i></i><cite>Id. at 69</cite>, 526.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA promulgated the final set of nine images &mdash; one for each warning
statement &mdash; by regulations issued on June 22, 2011. <i>See</i> Required Warnings
for Cigarette Packages and Advertisements, 76 Fed.Reg. 36, 628 (June 22,
2011) (hereinafter Final Rule). FDA also required each graphic image to bear
the phone number of the National Cancer Institute's "Network of Tobacco
Cessation Quitlines," which uses the telephone portal "<cite>1-800-QUIT-NOW</cite>." <i></i><cite>Id.
at 36</cite>, 681.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA based its selection of the final images on an 18,000-person
internet-based consumer study it commissioned. The study divided respondents
into two groups: a control group that was shown the new text in the format
of the current warnings (located on the side of cigarette packages), and a
separate treatment group that was shown the proposed graphic warnings, which
included the new text, the accompanying graphic image, and the
<cite>1-800-QUIT-NOW</cite> number. <i></i><cite>Id. at 36</cite>, 638. Each group then answered questions
designed to assess, among other things, whether the graphic warnings,
relative to the text-only control, (1) increased viewers' intention to quit
or refrain from smoking; (2) increased viewers' knowledge of the health
risks of smoking or secondhand smoke; and (3) were "salient," which FDA
defined in part as causing viewers to feel "depressed," "discouraged," or
"afraid." <b><i><cite>Id</cite>.</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In selecting these nine images, FDA reviewed and responded to over a
thousand public comments, including joint comments submitted by
plaintiffs-appellees RJ Reynolds, Lorillard, and Commonwealth Brands. <i>See</i>
<i></i><cite>id. at 36</cite>, 629. Several comments &mdash; including
<span CLASS="page_no" data-cite="402 us appeals dc 443" data-cite-type="SecondaryFederalReporter" data-cite-pageno="443" data-primary-citation="402 U.S. App. D.C. 438">[**443]</span> <span CLASS="page_no" data-cite="696 f 3d 1210" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1210" data-primary-citation="696 F.3d 1205">[*1210]</span> 
comments from cancer researchers, nonprofits, and academics &mdash; criticized the
single exposure study design, noting it prevented the government from
assessing the long-term or actual effects of the proposed warnings. Two of
these comments recommended FDA conduct longitudinal research or post-market
surveillance to assess actual long-term effects. <i>Id.</i> at 36, 639. FDA
conceded the study did not permit it to reach "firm" conclusions about the
"long-term, real-world effects" of the proposed warnings, but claimed the
existing scientific literature "provides a substantial basis for our
conclusion that the required warnings will effectively communicate the
health risks of smoking, <span CLASS="page_no" data-cite="2012 bl 217700 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> thereby encouraging smoking cessation and
discouraging smoking initiation." <i>Id.</i> Still other comments asserted that
FDA's research study failed to provide evidence that the proposed warnings
would actually affect smoking rates, significantly affect consumers
knowledge of the risks of smoking, or bring about actual behavior change.
<i>See id.</i> at 36, 640. But FDA disagreed, again relying on the "substantial
research" showing the effectiveness of similar graphic health warnings in
other countries. <i>Id.</i> (citing Proposed Rule at 69, 531-34).<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Another
comment asserted that the study's selection bias constituted a serious
methodological flaw. Namely, participants were recruited from an internet
panel and offered the opportunity to participate in an FDA-sponsored
research study. <i>Id.</i> at 36, 643. FDA avoided the substance of this argument
by conceding that its study "provides insight on the relative effectiveness
of the various warnings under consideration," not on the "absolute effects
of the warnings in general." <b><i>Id.</i></b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Some comments also criticized the lack of statistical evidence supporting
FDA's belief that requiring cigarette packages to bear the graphic warnings
would reduce smoking rates. <i>See id.</i> For example, the Companies noted that
the Canadian data revealed no statistically significant decline in smoking
rates for adolescents and adults after the introduction of similar graphic
warnings, which implied that the warnings were ineffective and that FDA's
warnings would be ineffective as well. <i>Id.</i> FDA summarily disagreed, stating
that the images it selected would satisfy its "primary goal, which is to
effectively convey the negative health consequences of smoking on cigarette
packages and in advertisements," which can help "both to discourage
nonsmokers . . . from initiating cigarette use and to encourage current
smokers to consider cessation." Final Rule at 36, 633. FDA also explained
that the data from Canada did not indicate that the warnings had been
ineffective, because other studies showed that the warnings had been
"effective at providing . . . smokers with health information, making
<span CLASS="page_no" data-cite="402 us appeals dc 444" data-cite-type="SecondaryFederalReporter" data-cite-pageno="444" data-primary-citation="402 U.S. App. D.C. 438">[**444]</span> <span CLASS="page_no" data-cite="696 f 3d 1211" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1211" data-primary-citation="696 F.3d 1205">[*1211]</span> 
consumers think about the health effects of smoking, and increasing smokers'
motivations to quit smoking." <i>Id.</i> at 36, 634.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After FDA finalized the Rule, the Companies filed suit in the district
court, claiming the cigarette warnings required under the Act and FDA's
implementing regulations violated the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment. The district court
granted the Companies' motion for a preliminary injunction on November 7,
2011, and subsequently granted their motion for summary judgment. FDA
appeals, and we review <i>de novo</i> the district court's decision to grant
summary judgment. <i>Davis v. Pension Benefit Guar. Corp.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1BAMQC003?jcsearch=571%20f%203d%201288&amp;summary=yes#jcite">571 F.3d 1288</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1BAMQC003?jcsearch=571%20f%203d%201288&amp;summary=yes#jcite">1291</a>
(D.C.Cir.2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II. Level of Scrutiny</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Companies do not dispute Congress's authority to require health
warnings on cigarette packages, nor do they challenge the substance of any
of the nine textual statements mandated by the Act. The only question before
us is whether FDA's promulgation of the graphic warning labels &mdash; which
incorporate <span CLASS="page_no" data-cite="2012 bl 217700 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> the textual warnings, a corresponding graphic image, and the
"<cite>1-800-QUIT-NOW</cite>" cessation hotline number &mdash; violates the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment. We
begin our analysis by determining the applicable level of scrutiny.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Both the right to speak and the right to refrain from speaking are
"complementary components of the broader concept of individual freedom of
mind" protected by the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment. <i>Wooley v. Maynard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9B5?jcsearch=430%20us%20705&amp;summary=yes#jcite">430 U.S. 705</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9B5?jcsearch=430%20us%20705&amp;summary=yes#jcite">714</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=97%20supreme%20court%201428&amp;summary=yes#jcite">97 S.Ct. 1428</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9B5?jcsearch=51%20l%20ed%202d%20752&amp;summary=yes#jcite">51 L.Ed.2d 752</a> (1977). Any attempt by the government
either to compel individuals to express certain views, <i>see id.</i> at 714-15,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=97%20supreme%20court%201428&amp;summary=yes#jcite">97 S.Ct. 1428</a>, or to subsidize speech to which they object, <i>see United</i>
<i>States v. United Foods, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=533%20us%20405&amp;summary=yes#jcite">533 U.S. 405</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=533%20us%20405&amp;summary=yes#jcite">410-11</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=121%20supreme%20court%202334&amp;summary=yes#jcite">121 S.Ct. 2334</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=150%20l%20ed%202d%20438&amp;summary=yes#jcite">150 L.Ed.2d 438</a> (2001), is subject to strict scrutiny. The general rule
"that the speaker has the right to tailor the speech[] applies not only to
expressions of value, opinion, or endorsement, but equally to statements of
fact the speaker would rather avoid." <i>Hurley v. Irish-Am. Gay, Lesbian &amp;</i>
<i>Bi-sexual Grp. of Bos.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOJ?jcsearch=515%20us%20557&amp;summary=yes#jcite">515 U.S. 557</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOJ?jcsearch=515%20us%20557&amp;summary=yes#jcite">573-74</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOJ?jcsearch=115%20supreme%20court%202338&amp;summary=yes#jcite">115 S.Ct. 2338</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOJ?jcsearch=132%20l%20ed%202d%20487&amp;summary=yes#jcite">132 L.Ed.2d 487</a> (1995). This holds true whether individuals, <i>see W. Va.</i>
<i>State Bd. of Educ. v. Barnette</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C0JV?jcsearch=319%20us%20624&amp;summary=yes#jcite">319 U.S. 624</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C0JV?jcsearch=319%20us%20624&amp;summary=yes#jcite">642</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C0JV?jcsearch=63%20supreme%20court%201178&amp;summary=yes#jcite">63 S.Ct. 1178</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=87%20l%20ed%201628&amp;summary=yes#jcite">87 L.Ed. 1628</a> (1943), or corporations, <i>see Pac. Gas &amp; Elec. Co. v. Pub.</i>
<i>Utils. Comm'n</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">475 U.S. 1</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">16</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=106%20supreme%20court%20903&amp;summary=yes#jcite">106 S.Ct. 903</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=89%20l%20ed%202d%201&amp;summary=yes#jcite">89 L.Ed.2d 1</a> (1986) (plurality
opinion), are being compelled to speak.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This case contains elements of compulsion and forced subsidization. The
Companies contend that, to the extent the graphic warnings go beyond the
textual warnings to shame and repulse smokers and denigrate smoking as an
antisocial act, the message is ideological and not informational. "[B]y
effectively shouting well-understood information to consumers," they
explain, "FDA is communicating an ideo-logical message, a point of view on
how people should live their lives: that the risks from smoking outweigh the
pleasure that smokers derive from it, and that smokers make bad personal
decisions, and should stop smoking." In effect, the graphic images are not
warnings, but admonitions: "[D]on't buy or use this product"<a HREF="#fn500" name="fnref_fn500">[fn5]</a> No one
doubts the government can
<span CLASS="page_no" data-cite="402 us appeals dc 445" data-cite-type="SecondaryFederalReporter" data-cite-pageno="445" data-primary-citation="402 U.S. App. D.C. 438">[**445]</span> <span CLASS="page_no" data-cite="696 f 3d 1212" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1212" data-primary-citation="696 F.3d 1205">[*1212]</span> 
promote smoking cessation programs; can use shock, shame, and moral
opprobrium to discourage people from becoming smokers; and can use its
taxing and regulatory authority to make smoking economically prohibitive and
socially onerous. And the government can certainly require that consumers be
fully informed about the dangers of hazardous products. But this case raises
novel questions about the scope of the government's authority to force the
manufacturer of a product to go beyond making purely factual and accurate
commercial disclosures and undermine its own economic interest &mdash; in this
case, by making "every single pack of cigarettes in the country [a] mini
billboard" for the government's anti-smoking message.<a HREF="#fn600" name="fnref_fn600">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even assuming the Companies' marketing efforts (packaging, branding, and
other advertisements) can be properly classified as commercial speech, and
thus subject to less robust <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment protections, a thorny question
remains: how much leeway should this Court grant the government when it
seeks to compel a product's manufacturer to convey the state's subjective &mdash;
and perhaps even ideological &mdash; view that consumers should reject this
otherwise legal, but disfavored, product? Neither the Act nor the agency's
regulation squarely <span CLASS="page_no" data-cite="2012 bl 217700 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> addresses this question. However, for present purposes,
we can assume, without deciding, that <i>if</i> such compulsion is constitutionally
permissible, the state's actions must still withstand the applicable level
of scrutiny.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Courts have recognized a handful of "narrow and well-understood
exceptions" to the general rule that content-based speech regulations &mdash;
including compelled speech &mdash; are subject to strict scrutiny. <i>See Turner</i>
<i>Broad. Sys., Inc. v. FCC</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">512 U.S. 622</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">641</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=114%20supreme%20court%202445&amp;summary=yes#jcite">114 S.Ct. 2445</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCKG?jcsearch=129%20l%20ed%202d%20497&amp;summary=yes#jcite">129 L.Ed.2d 497</a>
(1994). There are two primary exceptions in the commercial speech context.
First, "purely factual and un-controversial" disclosures are permissible if
they are "reasonably related to the State's interest in preventing deception
of consumers," provided the requirements are not "unjustified or unduly
burdensome." <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>. Second, restrictions
on commercial speech are subject to less stringent review than restrictions
on other types of speech. For a statute burdening commercial speech to
survive, the government must affirmatively prove that (1) its asserted
interest is substantial, (2) the restriction directly and materially
advances that interest, and (3) the restriction is narrowly tailored. <i>See</i>
<i>Cent. Hudson Gas &amp; Elec. Corp. v. Pub. Serv. Comm'n</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. 557</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">566</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=65%20l%20ed%202d%20341&amp;summary=yes#jcite">65 L.Ed.2d 341</a> (1980). While this test is not quite as
demanding as strict scrutiny, it is significantly more stringent than
<i>Zauderer's</i> standard, which is akin to rational-basis review.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court concluded the graphic warnings were "<i>not</i> the type of
purely factual and uncontroversial" disclosures reviewable under the less
stringent <i>Zauderer</i> standard.
<span CLASS="page_no" data-cite="696 f 3d 1213" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1213" data-primary-citation="696 F.3d 1205">[*1213]</span> 
<i>R.J. Reynolds Tobacco Co. v. FDA<span CLASS="page_no" data-cite="402 us appeals dc 446" data-cite-type="SecondaryFederalReporter" data-cite-pageno="446" data-primary-citation="402 U.S. App. D.C. 438">[**446]</span> </i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=845%20f%20supp%202d%20266&amp;summary=yes#jcite">845 F.Supp.2d 266</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=845%20f%20supp%202d%20266&amp;summary=yes#jcite">272-73</a> (D.D.C.2012)
(hereinafter "Merits Opinion"). Applying strict scrutiny, the court held
that FDA failed to satisfy its burden of demonstrating that the Rule is
narrowly tailored to achieve a compelling government interest. <i>See id.</i> at
275-77. FDA argues that the district court erred in finding the <i>Zauderer</i>
standard inapplicable. Alternatively, it contends that the district court
erred by failing to apply the intermediate-level scrutiny generally afforded
to commercial speech, and that the graphic warnings pass constitutional
muster under <i>Central Hudson.</i> We address each argument in turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>a. Applicability of the Zauderer Standard</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Zauderer</i>, the Court applied a lower level of scrutiny to regulations
requiring attorneys to fully disclose information about the actual cost and
consequences of services. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651-52</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>. Noting that
the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment's protection of commercial speech is premised on its
informational value to consumers, the Court reasoned that an advertiser's
constitutional interest in <i>not</i> providing additional factual information was
"minimal." <i>Id.</i> at 651, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>. Although the Court acknowledged that
"unjustified or unduly burdensome disclosure requirements might offend the
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment by chilling protected commercial speech," it "h[e]ld that an
advertiser's rights are adequately protected as long as disclosure
requirements are reasonably related to the State's interest in preventing
deception of consumers." <i>Id.; see also Milavetz, Gallop &amp; <span CLASS="page_no" data-cite="2012 bl 217700 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> Milavetz, P.A. v.</i>
<i>United States</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. 1324</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">1340</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=176%20l%20ed%202d%2079&amp;summary=yes#jcite">176 L.Ed.2d 79</a> (2010)
(applying the <i>Zauderer</i> standard to disclosure requirements "intended to
combat the problem of inherently misleading commercial advertisements").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court has never applied <i>Zauderer</i> to disclosure requirements
not designed to correct misleading commercial speech. FDA argues that
<i>Zauderer's</i> lenient standard of scrutiny applies to regulations that serve a
different governmental interest: disclosure of the health and safety risks
associated with commercial products. <i>See</i> Appellant's Br. at 26.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But by its own terms, <i>Zauderer's</i> holding is limited to cases in which
disclosure requirements are "reasonably related to the State's interest in
preventing deception of consumers." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>.
<i>Zauderer</i> "carries no authority for a mandate unrelated to the interest in
avoiding misleading or incomplete commercial messages." <i>Glickman v. Wileman</i>
<i>Bros. &amp; Elliott, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCUO?jcsearch=521%20us%20457&amp;summary=yes#jcite">521 U.S. 457</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCUO?jcsearch=521%20us%20457&amp;summary=yes#jcite">491</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=117%20supreme%20court%202130&amp;summary=yes#jcite">117 S.Ct. 2130</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCUO?jcsearch=138%20l%20ed%202d%20585&amp;summary=yes#jcite">138 L.Ed.2d 585</a>
(1997) (Souter, J., dissenting, joined by Rehnquist, C.J., and Scalia and
Thomas, JJ.) (explaining why <i>Zauderer</i> was inapplicable in that case).<a HREF="#fn700" name="fnref_fn700">[fn7]</a>
In <i>United States v. United Foods</i>, for example, the Court declined to apply
the <i>Zauderer</i> standard when evaluating a federal law requiring mushroom
producers to pay an assessment to support generic advertising. The Court
distinguished <i>Zauderer</i> because there was no suggestion "that the mandatory
assessments imposed to require one group of private persons to pay for
speech by others are somehow necessary to make voluntary advertisements
non-misleading for consumers." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=533%20us%20405&amp;summary=yes#jcite">533 U.S. at 416</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=121%20supreme%20court%202334&amp;summary=yes#jcite">121 S.Ct. 2334</a>. And as the
Court explained in <i>Pacific Gas</i>, "[n]othing in <i>Zauderer</i> suggests . . . that
<span CLASS="page_no" data-cite="402 us appeals dc 447" data-cite-type="SecondaryFederalReporter" data-cite-pageno="447" data-primary-citation="402 U.S. App. D.C. 438">[**447]</span> <span CLASS="page_no" data-cite="696 f 3d 1214" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1214" data-primary-citation="696 F.3d 1205">[*1214]</span> 
the State is equally free to require [entities] to carry the messages of
third parties, where the messages themselves are biased against or are
expressly contrary to the [entity's] views." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">475 U.S. at 15</a> n. 12,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=106%20supreme%20court%20903&amp;summary=yes#jcite">106 S.Ct. 903</a> (plurality opinion).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Ibanez v. Florida Department of Business and Professional Regulation</i> also
suggests that <i>Zauderer</i> should be construed to apply <i>only</i> when the government
affirmatively demonstrates that an advertisement threatens to deceive
consumers. In that case, the state Board of Accountancy contended that an
attorney's use of her Certified Financial Planner designation in an
advertisement was "potentially misleading," and thus entitled the Board to
require her to include a disclaimer. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=512%20us%20136&amp;summary=yes#jcite">512 U.S. 136</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=512%20us%20136&amp;summary=yes#jcite">146</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=114%20supreme%20court%202084&amp;summary=yes#jcite">114 S.Ct. 2084</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=129%20l%20ed%202d%20118&amp;summary=yes#jcite">129 L.Ed.2d 118</a> (1994). But the Court declined to apply <i>Zauderer</i>, finding
that "given the state of this record," the Board failed "to point to any
harm that is potentially real, not purely hypothetical." <i>Id.</i> Put simply, the
government could not seek review under the lenient <i>Zauderer</i> standard absent
a showing that the advertisement at issue would likely mislead consumer's.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In fact, the Court's <i>only</i> recent application of the <i>Zauderer</i> standard
involved a disclosure requirement that "share[d] the essential features of
the rule at issue in <i>Zauderer:' Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>. In <i>Milavetz</i>, a
law firm challenged a provision of the Bankruptcy Abuse Prevention and
Consumer Protection Act of 2005 ("BAPCPA") that required professionals
qualifying as debt relief agencies to "clearly and conspicuously disclose in
any <span CLASS="page_no" data-cite="2012 bl 217700 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> advertisement of bankruptcy assistance services . . . that the services
or benefits are with respect to bankruptcy relief under this title."
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X12704U003?jcsearch=11%20U.S.C.%20%20528(a)(3)&amp;summary=yes#jcite">11 U.S.C. &sect; 528</a>(a)(3). BAPCPA also required qualifying professionals to
state that "[w]e are a debt relief agency. We help people file for
bankruptcy relief under the Bankruptcy Code." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X12704U003?jcsearch=11%20U.S.C.%20%20528(a)(4)&amp;summary=yes#jcite">Id. &sect; 528(a)(4)</a>. The Court
upheld the statute's disclosure requirement because, as in <i>Zauderer</i>, the law
firm's advertisements were "inherently misleading" &mdash; in this case, because
they "promis[ed] . . . debt relief without any reference to the possibility
of filing for bankruptcy, which has inherent costs." <i>Milavetz</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>. One Justice even cautioned against interpreting the
Court's holding as a "presumptive[] endorse[ment of] laws requiring the use
of government-scripted disclaimers in commercial advertising," noting that
<i>Zauderer</i> does not stand for the proposition that government "can
constitutionally compel the use of a scripted disclaimer in any circumstance
in which its interest in preventing consumer deception might plausibly be at
stake." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20S.%20Ct.%201324&amp;summary=yes#jcite">Id. at 1343-44</a> (Thomas, J., concurring in part and concurring in the
judgment).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Zauderer, Ibanez</i>, and <i>Milavetz</i> thus establish that a disclosure
requirement is only appropriate if the government shows that, absent a
warning, there is a self-evident &mdash; or at least "potentially real" &mdash; danger
that an advertisement will mislead consumers. <i>Ibanez</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=512%20us%20136&amp;summary=yes#jcite">512 U.S. at 146</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=114%20supreme%20court%202084&amp;summary=yes#jcite">114 S.Ct. 2084</a>. In this case, the proposed disclosure requirements would
apply to both cigarette advertisements and cigarette packages. The Act bans
any labeling or advertising representing that any tobacco product "presents
a lower risk of tobacco-related disease or is less harmful than one or more
other commercially marketed tobacco products," "contains a reduced level of
a substance or presents a reduced exposure to a substance," or "does not
contain or is free of a substance." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HBU003?jcsearch=21%20usc%20387k&amp;summary=yes#jcite">21 U.S.C. &sect; 387k</a>. The Act also bans
advertising or labeling using the descriptors "light," "mild," "low," or
similar descriptors. <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HBU003?jcsearch=21%20U.S.C.%20%20387k&amp;summary=yes#jcite">Id</a>.</i> In light of these restrictions, and in the absence
of any congressional findings
<span CLASS="page_no" data-cite="402 us appeals dc 448" data-cite-type="SecondaryFederalReporter" data-cite-pageno="448" data-primary-citation="402 U.S. App. D.C. 438">[**448]</span> <span CLASS="page_no" data-cite="696 f 3d 1215" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1215" data-primary-citation="696 F.3d 1205">[*1215]</span> 
on the misleading nature of cigarette packaging itself, there is no
justification under <i>Zauderer</i> for the graphic warnings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The dissent's argument that cigarette packages and other advertisements
that fail to prominently display the negative health consequences of smoking
are mis-leading, <i>see</i> Dissent at 1228-29, seems to blame the industry for
playing by the government's rules. The Companies have never argued that <i>no</i>
disclosure requirements are warranted; they merely object to the form and
content of the specific requirements proposed by the FDA. Indeed, it seems
likely the FDA did not make any such claims because the industry has
complied precisely with all of the government's previous disclosure
requirements, and continues to do so. Moreover, the Companies generally
acknowledge the need for effective warnings and concede in their brief that
they would be amenable to a number of new disclosure requirements, including
putting the Act's new text on the side of packages, the bottom front of
packages and <span CLASS="page_no" data-cite="2012 bl 217700 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> advertisements, or using less shocking graphics. Appellees' Br.
at 58.<a HREF="#fn800" name="fnref_fn800">[fn8]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The amicus States suggest that the graphic warnings be evaluated in the
context of the years of deception that preceded them.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> States' Br. at 7.
Citing <i>Warner-Lambert Co. v. FTC</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20f%202d%20749&amp;summary=yes#jcite">562 F.2d 749</a> (D.C.Cir.1977) they claim
this Court has found that even advertisements that do not appear deceptive
in isolation can constitute "part of a continuing deception of the public"
absent highly visible warnings. <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20F.2d%20749&amp;summary=yes#jcite">Id. at 769</a>. But the States' argument
overlooks the broader context of that decision. <i>Warner-Lambert</i> involved a
petition for review of an FTC order requiring the Warner-Lambert company to
cease and desist from advertising that its product, Listerine mouthwash,
prevents, cures, or alleviates the common cold. <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20F.2d%20749&amp;summary=yes#jcite">Id. at 752</a>. As a remedial
measure, the Commission required Warner-Lambert to include the following
disclosure in every future advertisement for Listerine for a defined period:
"Contrary to prior advertising, Listerine will not help prevent colds or
sore throats or lessen their severity." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20F.2d%20749&amp;summary=yes#jcite">Id. at 753</a>. In other words, the
disclosure statement was required as part of a corrective order which the
Commission found necessary to "dissipate the effects of respondent's
deceptive representations." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20F.2d%20749&amp;summary=yes#jcite">Id. at 769</a>; <i>see also Novartis Corp. v. FTC</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3FJF7?jcsearch=223%20f%203d%20783&amp;summary=yes#jcite">223 F.3d 783</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3FJF7?jcsearch=223%20f%203d%20783&amp;summary=yes#jcite">788-89</a> (D.C.Cir.2000) (upholding the Commission's corrective
order imposing disclosure requirements on drug manufacturer).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  By contrast, FDA does not frame <i>this</i> rule as a remedial measure designed
to counteract specific deceptive claims made by the Companies, nor did it
offer a remedial justification for the graphic warnings during the
rulemaking proceeding. While the Companies' representations about
<span CLASS="page_no" data-cite="402 us appeals dc 449" data-cite-type="SecondaryFederalReporter" data-cite-pageno="449" data-primary-citation="402 U.S. App. D.C. 438">[**449]</span> <span CLASS="page_no" data-cite="696 f 3d 1216" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1216" data-primary-citation="696 F.3d 1205">[*1216]</span> 
"light" or "low tar" cigarettes might have been misleading, <i>see United</i>
<i>States v. Philip Morris USA Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d 1095</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">1124-26</a> (D.C.Cir.2009), the
Act now prohibits such statements. <i>See</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HBU003?jcsearch=21%20usc%20387k&amp;summary=yes#jcite">21 U.S.C. &sect; 387k</a>. Unlike in
<i>Warner-Lambert</i>, FDA has not shown that the graphic warnings were designed to
correct any false or misleading claims made by cigarette manufacturers in
the past.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> Nor did it show that absent disclosure, consumers would
likely be deceived by the Companies' packaging in the future. Rather, FDA
framed the warnings as general disclosures about the negative health effects
of smoking. The warnings thus represent an ongoing effort to discourage
consumers from buying the Companies' products, rather than, as in
<i>Warner-Lambert</i>, a measure designed to combat specific deceptive claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Moreover, the graphic warnings do not constitute the type of "purely
factual and uncontroversial" information, <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>, or "accurate statement[s]," <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>, to
which the <i>Zauderer</i> standard may be applied. The disclosures approved in
<i>Zauderer</i> and <i>Milavetz</i> were clear statements that were both indisputably
accurate and not subject to misinterpretation by consumers. <i>See Zauderer</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 633</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a> (describing the disciplinary rule that
required "that any advertisement that mentions contingent-fee rates must
disclos[e] whether percentages are computed before or after deduction of
court costs and expenses"); <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1330</a> (describing BAPCPA
<span CLASS="page_no" data-cite="2012 bl 217700 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> disclosure requirements, including, <i>inter alia</i>, a statement that "[w]e are a
debt relief agency. We help people file for relief under the Bankruptcy
Code.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA's images are a much different animal. FDA concedes that the images
are not meant to be interpreted literally, but rather to symbolize the
textual warning statements, which provide "additional context for what is
shown." Final Rule at 36, 655. But many of the images chosen by FDA could be
misinterpreted by consumers. For example, the image of a man smoking through
a tracheotomy hole might be misinterpreted as suggesting that such a
procedure is a common consequence of smoking &mdash; a more logical interpretation
than FDA's contention that it symbolizes "the addictive nature of
cigarettes," which requires significant extrapolation on the part of the
consumers. <i></i><cite>Id. at 36</cite>, 649. Moreover, the graphic warnings are not "purely"
factual because &mdash; as FDA tacitly admits &mdash; they are primarily intended to
evoke an emotional response, or, at most, shock the viewer into retaining
the information in the text warning. <i>See</i> Appellant's Br. at 33 (citing
research showing that "pictures are easier to remember than words"); <i></i><cite>id. at
38</cite> (citing FDA's finding that a substantial body of scientific literature
shows that emotional responses, such as worry and disgust, "reliably predict
the likelihood that consumers will understand and appreciate the substance
of the warnings").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In fact, many of the images do not convey <i>any</i> warning information at all,
much less make an "accurate statement" about cigarettes. For example, the
images of a woman crying, a small child, and the man wearing a T-shirt
emblazoned with the words "I QUIT" do not offer any information about the
health effects of smoking. And the "<cite>1-800-QUIT-NOW</cite>" number, when presented
without any explanation about the services provided on the hotline, hardly
sounds like an unbiased source of information. These inflammatory images and
the provocatively-named hotline can
<span CLASS="page_no" data-cite="402 us appeals dc 450" data-cite-type="SecondaryFederalReporter" data-cite-pageno="450" data-primary-citation="402 U.S. App. D.C. 438">[**450]</span> <span CLASS="page_no" data-cite="696 f 3d 1217" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1217" data-primary-citation="696 F.3d 1205">[*1217]</span> 
not rationally be viewed as pure attempts to convey information to
consumers. They are unabashed attempts to evoke emotion (and perhaps
embarrassment) and browbeat consumers into quitting. <i>See</i> Final Rule at 36,
697 ("[R]isk information is most readily conveyed by warnings that elicit .
. . strong emotional and cognitive reactions. . . .") . While none of these
images are patently false, they certainly do not impart purely factual,
accurate, or un-controversial information to consumers. Consequently, the
images fall outside the ambit of <i>Zauderer.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>b. Applicability of Central Hudson</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because this case does not fall within the narrow enclave carved out by
<i>Zauderer</i>, we must next determine which level of scrutiny &mdash; strict or
intermediate &mdash; is appropriate. The district court held that compelled speech
that falls outside the <i>Zauderer</i> framework is subject to strict scrutiny. See
Merits Op. at 274-75. <i>See also Disc. Tobacco City &amp; Lottery, Inc. v. United</i>
<i>States</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d 509</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">554</a> (6th Cir.2012) (deciding between applying strict
scrutiny or <i>Zauderer</i> to compelled commercial speech); <i>Entmt Software Ass'n</i>
<i>v. Blagojevich</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X160QP2003?jcsearch=469%20f%203d%20641&amp;summary=yes#jcite">469 F.3d 641</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X160QP2003?jcsearch=469%20f%203d%20641&amp;summary=yes#jcite">652</a> (7th Cir.2006) (same). The government <span CLASS="page_no" data-cite="2012 bl 217700 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> argues
that we should view the graphic warnings as restrictions on commercial
speech, which are analyzed under the less rigorous standard established by
<i>Central Hudson.</i> Despite the contrary views of other circuits, our governing
precedent makes clear that <i>Central Hudson</i> is the appropriate standard.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  This Court recently evaluated the constitutionality of compelled
commercial speech in <i>United States v. Philip Morris</i>, where it reviewed a
district court order requiring the defendant tobacco manufacturers to
publish corrective statements on their websites, in newspapers, and on major
television networks. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1142-43</a>. This Court began by noting that
"[b]ecause commercial speech receives a lower level of protection under the
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment, burdens imposed on it receive a lower level of scrutiny
from the courts." <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20F.3d%201095&amp;summary=yes#jcite">Id</a>.</i> After acknowledging that "the standard for assessing
burdens on commercial speech has varied," the Court concluded that "the
Supreme Court's bottom line is clear: the government must affirmatively
demonstrate its means are narrowly tailored to achieve a substantial
government goal." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20F.3d%201095&amp;summary=yes#jcite">Id. at 1143</a>. <i>See also Novartis Corp.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3FJF7?jcsearch=223%20f%203d%20783&amp;summary=yes#jcite">223 F.3d at 789</a>
(evaluating a corrective remedy involving corrective statements under
<i>Central Hudson</i>). Because this case also involves a compelled commercial
disclosure, we follow the lead of <i>Philip Morris</i> and apply the intermediate
standard set forth in <i>Central Hudson.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>III. Evaluating the Graphic Warnings Under Intermediate Scrutiny</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under <i>Central Hudson</i>, the government must first show that its asserted
interest is "substantial." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> If so, the
Court must determine "whether the regulation directly advances the
governmental interest asserted, and whether it is not more extensive than is
necessary to serve that interest." <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20U.S.%20557&amp;summary=yes#jcite">Id</a>.</i> The party seeking to uphold a
restriction on commercial speech bears the burden of justifying it.
<i>Edenfield v. Fane</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. 761</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">770-71</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=123%20l%20ed%202d%20543&amp;summary=yes#jcite">123 L.Ed.2d 543</a>
(1993). Because this case involves a challenge to final agency action,
<span CLASS="page_no" data-cite="402 us appeals dc 451" data-cite-type="SecondaryFederalReporter" data-cite-pageno="451" data-primary-citation="402 U.S. App. D.C. 438">[**451]</span> <span CLASS="page_no" data-cite="696 f 3d 1218" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1218" data-primary-citation="696 F.3d 1205">[*1218]</span> 
the Administrative Procedure Act governs our review of the record.
<i>See</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEGP3C003?jcsearch=5%20U.S.C.%20%20706(2)(B)&amp;summary=yes#jcite">5 U.S.C. &sect; 706</a>(2)(B) (providing that the APA applies to allegations that
agency action is "contrary to constitutional right, power, privilege, or
immunity"). The APA requires us to "hold unlawful and set aside agency
action, findings, and conclusions found to be . . . unsupported by
substantial evidence." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEGP3C003?jcsearch=5%20U.S.C.%20%20706(2)&amp;summary=yes#jcite">5 U.S.C. &sect; 706</a>(2).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Unlike rational-basis review, the <i>Central Hudson</i> standard does not permit
this Court to "supplant the precise interests put forward by [FDA] with
other suppositions." <i>Edenfield</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. at 768</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>. We thus
begin by identifying FDA's asserted interests.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A review of the statute and the administrative record makes clear that the
graphic warnings are intended to encourage current smokers to quit and
dissuade other consumers from ever buying cigarettes. One of the Act's many
stated purposes is "promot[ing] cessation to reduce disease risk and the
social costs associated with tobacco-related diseases." Act <cite>&sect; 3.9</cite>. The <i>only</i>
explicitly asserted interest in either the Proposed or Final Rule is an
interest in reducing smoking rates. The Proposed Rule states in its preamble
that the <span CLASS="page_no" data-cite="2012 bl 217700 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> government has a "substantial interest in reducing the number of
Americans, particularly children and adolescents, who use cigarettes and
other tobacco products." Proposed Rule at 69, 525. And the preamble to the
Final Rule reiterates the same interest. Final Rule at 36, 629.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
Although counsel attempted to disclaim this interest at oral argument, the
administrative record shows otherwise: the primary objective of the Rule was
"both to discourage nonsmokers from initiating cigarette use and to
encourage current smokers to consider quitting." <i></i><cite>Id. at 36</cite>, 630.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Assuming FDA's interest in reducing smoking rates is substantial,<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> we
next evaluate whether FDA has offered substantial evidence showing that the
graphic warning requirements "directly advance[] the governmental interest
asserted," <i>Cent. Hudson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>, to a "material
degree," <i>Fl. Bar v. Went For It, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=515%20us%20618&amp;summary=yes#jcite">515 U.S. 618</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=515%20us%20618&amp;summary=yes#jcite">626</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=115%20supreme%20court%202371&amp;summary=yes#jcite">115 S.Ct. 2371</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=132%20l%20ed%202d%20541&amp;summary=yes#jcite">132 L.Ed.2d 541</a> (1995). The government bears the burden of justifying its
attempt to restrict commercial speech, <i>Edenfield</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. at 770</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>, and its burden is not light. A restriction that "provides
only ineffective or remote support for the government's purposes," <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20U.S.%20761&amp;summary=yes#jcite">id. at
770</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>, is not
<span CLASS="page_no" data-cite="696 f 3d 1219" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1219" data-primary-citation="696 F.3d 1205">[*1219]</span> 
<span CLASS="page_no" data-cite="402 us appeals dc 452" data-cite-type="SecondaryFederalReporter" data-cite-pageno="452" data-primary-citation="402 U.S. App. D.C. 438">[**452]</span> sufficient, and the government cannot satisfy its burden "by mere
speculation or conjecture." <i>Rubin v. Coors Brewing Co.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">514 U.S. 476</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">487</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=115%20supreme%20court%201585&amp;summary=yes#jcite">115 S.Ct. 1585</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=131%20l%20ed%202d%20532&amp;summary=yes#jcite">131 L.Ed.2d 532</a> (1995). The requirement that a restriction
directly advance the asserted interest is "critical," because without it,
the government "could [interfere with] commercial speech in the service of
other objectives that could not themselves justify a burden on commercial
expression." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA has not provided a shred of evidence &mdash; much less the "substantial
evidence" required by the APA &mdash; showing that the graphic warnings will
"directly advance" its interest in reducing the number of Americans who
smoke. FDA makes much of the "international consensus" surrounding the
effectiveness of large graphic warnings, but offers no evidence showing that
such warnings have <i>directly caused</i> a material decrease in smoking rates in
any of the countries that now require them. While studies of Canadian and
Australian youth smokers showed that the warnings on cigarette packs caused
a substantial number of survey participants to think &mdash; or think more &mdash; about
quitting smoking, Proposed Rule at 69, 532, and FDA might be correct that
intentions are a "necessary precursor" to behavior change, Final Rule at 36,
642, it is mere speculation to suggest that respondents who report increased
<i>thoughts</i> about quitting smoking will actually follow through on their
intentions. And at no point did these studies attempt to evaluate whether
the increased thoughts about smoking cessation led participants to actually
quit. Another Australian study reported increased quit <i>attempts</i> by survey
participants after that country enacted large graphic warnings, but found
"no association with short-term quit success." Proposed Rule at 69, 532.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Some Canadian and Australian studies indicated that large graphic warnings
<i>might</i> induce individual smokers to reduce consumption, or to help persons
who have already quit smoking remain abstinent. <i>See <cite>id</cite>.</i> But again, <span CLASS="page_no" data-cite="2012 bl 217700 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> the study
did not purport to show that the implementation of large graphic warnings
has <i>actually</i> led to a reduction in smoking rates.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA's reliance on this questionable social science is unsurprising when we
consider the raw data regarding smoking rates in countries that have enacted
graphic warnings. FDA claims that Canadian national survey data suggest that
graphic warnings may reduce smoking rates. But the strength of the evidence
is underwhelming, making FDA's claim somewhat misleading. In the year prior
to the introduction of graphic warnings, the Canadian national survey showed
that 24 percent of Canadians aged 15 or older smoked cigarettes. In 2001,
the year the warnings were introduced, the national smoking rate dropped to
22 percent, and it further dropped to 21 percent in 2002. <i></i><cite>Id. at 69</cite>, 532.
But the raw numbers don't tell the whole tale. FDA concedes it cannot
directly attribute <i>any</i> decrease in the Canadian smoking rate to the graphic
warnings because the Canadian government implemented other smoking control
initiatives, including an increase in the cigarette tax and new restrictions
on public smoking, during the same period. <i><cite>Id</cite>.</i> Although FDA maintains the
data "are suggestive" that large graphic warnings "may" reduce smoking
consumption, <i><cite>id</cite>.</i> it cannot satisfy its <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment burden with "mere
speculation and conjecture." <i>Rubin</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">514 U.S. at 487</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=115%20supreme%20court%201585&amp;summary=yes#jcite">115 S.Ct. 1585</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA's Regulatory Impact Analysis ("RIA")<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a> essentially concedes the
agency <span CLASS="page_no" data-cite="402 us appeals dc 453" data-cite-type="SecondaryFederalReporter" data-cite-pageno="453" data-primary-citation="402 U.S. App. D.C. 438">[**453]</span> lacks
<span CLASS="page_no" data-cite="696 f 3d 1220" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1220" data-primary-citation="696 F.3d 1205">[*1220]</span> 
any evidence showing that the graphic warnings are likely to reduce smoking
rates. One way in which the RIA analyzed the expected benefits of the Rule
was by comparing the impact of similar warnings introduced in Canada in
2000. <i>See</i> Final Rule at 36, 719-20. It (1) analyzed the change in smoking
trends in Canada before and after 2000; (2) assumed any difference in the
post-2000 change between Canada and the United States was solely
attributable to the introduction of graphic warnings; and (3) assumed
similar warnings would have an identical impact on U.S. smoking rates. <i>See</i>
<i></i><cite>id. at 36</cite>, 755. Describing its approach as "rudimentary," FDA acknowledged
that apart from differences in cigarette taxes, the RIA "d[<cite>id</cite>] not account
for potential confounding variables," <i></i><cite>id. at 36</cite>, 720-21, such as the
introduction of more stringent smoking bans and advertising restrictions in
Canada during the relevant time period, or the fact that Canadian cigarette
prices are generally higher than U.S. prices. Plaintiffs' Comment Letter on
Proposed Rule (Jan. 11, 2010) and Statement of Robert S. Maness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Logic dictates that these procedural shortcuts would, if anything, lead to
an overly optimistic prediction of the efficacy of the proposed graphic
warnings. Not so. The RIA estimated the new warnings would reduce U.S.
smoking rates by a mere 0.088%, Final Rule at 36, 721, a number the FDA
concedes is "in general not statistically distinguishable from zero." <i></i><cite>Id. at
36</cite>, 776. Indeed, because it had access to "very small data sets," FDA could
not even reject the statistical possibility that the Rule would have <i>no</i>
impact on U.S. smoking rates. <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA has thus presented <span CLASS="page_no" data-cite="2012 bl 217700 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> us with only two studies that directly evaluate the
impact of graphic warnings on actual smoking rates, and neither set of data
shows that the graphic warnings will "directly" advance its interest in
reducing smoking rates "to a material degree." <i>Rubin</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">514 U.S. at 487</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=115%20supreme%20court%201585&amp;summary=yes#jcite">115 S.Ct. 1585</a>. And one of the principal researchers on whom FDA relies
recently surveyed the relevant literature and conceded that "[t]here is no
way to attribute . . . declines [in smoking] to the new health warnings."
David Hammond, <i>Health Warnings Messages on Tobacco Products: A Review</i>, 20
Tobacco Control 327, 331 (2011), <i>available at</i>
http://tobaccocontrol.bmj.com/content/20/5/327.full.pdf In light of the
number of foreign jurisdictions that have enacted large graphic warning
labels, the dearth of data reflecting decreased smoking rates in these
countries is somewhat surprising, and strongly implies that such warnings
are <i>not</i> very effective at promoting cessation and discouraging initiation.
While APA review of final agency action is deferential, it surely does not
require us to accept a flawed interpretation of Canadian survey data or the
agency's own projected 0.088% decrease in the U.S. smoking rate as
"substantial evidence" that its warnings will advance its stated interest.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  FDA attempts to downplay the significance of the RIA by explaining that it
"must be included in all federal rule-making to improve the internal
management of the Federal Government," and that it "was not intended to
second-guess Congress's judgment regarding the value of new health
warnings." Pet. Reply Br. at 15-16.<a HREF="#fn1500" name="fnref_fn1500">[fn15]</a> FDA attempts to rehabilitate
<span CLASS="page_no" data-cite="402 us appeals dc 454" data-cite-type="SecondaryFederalReporter" data-cite-pageno="454" data-primary-citation="402 U.S. App. D.C. 438">[**454]</span> <span CLASS="page_no" data-cite="696 f 3d 1221" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1221" data-primary-citation="696 F.3d 1205">[*1221]</span> 
its findings by noting the analysis made only the "unremarkable point" that
it is "difficult [to] determine with statistical precision the relative
causal impact of the relevant contributing factors," particularly given the
very small data sets to which FDA had access. <i></i><cite>Id. at 16</cite>. But FDA cannot get
around the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment by pleading incompetence or futility. Because FDA
bears the burden of justifying its proposed restraint on speech, it cannot
claim &mdash; rather perversely &mdash; that its own analysis was irrelevant because it
lacked precision and was based on insufficient data. <i>Central Hudson</i> requires
FDA to find and present data supporting its claims <i>prior to</i> imposing a
burden on commercial speech.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Alternatively, FDA asserts an interest in "effectively communicating
health information" regarding the negative effects of cigarettes.
Appellant's Br. at 28. But as FDA concedes, this purported "interest"
describes only the <i>means</i> by which FDA is attempting to reduce smoking rates:
"[t]he goal of effectively communicating the risks of cigarette smoking is,
of course, related to the viewer's decision to quit, or never to start,
smoking." <i></i><cite>Id. at 47</cite>. The government's attempt to reformulate its interest as
purely informational is unconvincing, as an interest in "effective"
communication is too vague to stand on its own. Indeed, the government's
chosen buzzwords, which it reiterates through the rulemaking, prompt an
obvious question: "effective" in what sense? Allowing FDA to define
"effectiveness" <span CLASS="page_no" data-cite="2012 bl 217700 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> however it sees fit would not only render <i>Central Hudson's</i>
"substantial interest" requirement a complete nullity, but it would also
eviscerate the requirement that any restriction "directly advance" that
interest. <i>See</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. In this case, both the statute
and the Rule offer a barometer for assessing the effectiveness of the
graphic warnings &mdash; the degree to which they encourage current smokers to
quit and dissuade would-be smokers from taking up the habit. <i>See</i> Final Rule
at 36, 630, 36, 707-08. As such, FDA's interest in "effectively
communicating" the health risks of smoking is merely a description of the
means by which it plans to accomplish its goal of reducing smoking rates,
and not an independent interest capable of sustaining the Rule.<a HREF="#fn1600" name="fnref_fn1600">[fn16]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>IV. Conclusion</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the Proposed Rule, FDA lamented that their previous efforts to combat
the tobacco companies' advertising campaigns have been like bringing a
butter knife to a gun fight. According to the FTC, tobacco companies spent
approximately $12.49 billion on advertising and promotion in 2006 alone,
employing marketing and advertising experts to incorporate current trends
and target their messages toward certain demographics. Proposed Rule at 69,
531. The graphic warnings represent FDA's attempt to level the playing
field, not only by limiting the Companies' ability to advertise, but also by
forcing the Companies to bear the cost of disseminating an anti-smoking
message. But as the Supreme
<span CLASS="page_no" data-cite="402 us appeals dc 455" data-cite-type="SecondaryFederalReporter" data-cite-pageno="455" data-primary-citation="402 U.S. App. D.C. 438">[**455]</span> <span CLASS="page_no" data-cite="696 f 3d 1222" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1222" data-primary-citation="696 F.3d 1205">[*1222]</span> 
Court recently reminded us, "[t]hat the [government] finds expression too
persuasive does not permit it to quiet the speech or to burden its
messengers." <i>Sorrell v. IMS Health Inc.</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">2671</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a> (2011). The <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment requires the government not only
to state a substantial interest justifying a regulation on commercial
speech, but also to show that its regulation directly advances that goal.
FDA failed to present any data &mdash; much less the substantial evidence required
under the APA &mdash; showing that enacting their proposed graphic warnings will
accomplish the agency's stated objective of reducing smoking rates. The Rule
thus cannot pass muster under <i>Central Hudson.</i> The APA directs that we "shall
. . . set aside [the] agency action . . . found to be contrary to
constitutional right." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEGP3C003?jcsearch=5%20U.S.C.%20%20706(2)&amp;summary=yes#jcite">5 U.S.C. &sect; 706</a>(2). We therefore vacate the graphic
warning requirements and remand to the agency. In so doing, we also vacate
the permanent injunction issued by the district court, in furtherance of our
obligation to "set aside" the unlawful regulation. <i>See, e.g., N. Air Cargo</i>
<i>v. United States Postal Serv.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HDSI6003?jcsearch=674%20f%203d%20852&amp;summary=yes#jcite">674 F.3d 852</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HDSI6003?jcsearch=674%20f%203d%20852&amp;summary=yes#jcite">861</a> (D.C.Cir.2012) ("It was
quite anomalous [for the district court] to issue an injunction. When a
district court reverses agency action and determines that the agency acted
unlawfully, ordinarily the appropriate course is to identify a legal error
and then remand to the agency, because the role of the district court in
such situations is to act as an appellate tribunal").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The Companies also alleged the graphic warnings violated the
Administrative Procedure Act ("APA"), specifically <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEGOVK003?jcsearch=5%20U.S.C.%20%20553(b)(3)&amp;summary=yes#jcite">5 U.S.C. &sect; 553</a>(b)(3) and
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEGP3C003?jcsearch=5%20U.S.C.%20%20706(2)(A)&amp;summary=yes#jcite">706</a>(2)(A). <i>See</i> Compl. at 37. Because we hold the graphic warnings violate
the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment, we do not reach the Companies' APA claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> FDA originally appealed the district court's grant of the Companies
motion for a preliminary injunction, but that ruling was superseded by the
court's subsequent ruling on the merits.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Countries/jurisdictions that have implemented pictorial warning
requirements for tobacco packaging include Australia, Belgium, Brazil,
Brunei, Canada, Chile, Colombia, Cook Islands, Djibouti, Egypt, Hong Kong,
India, Iran, Jordan, Latvia, Malaysia, Mauritius, Mexico, Mongolia, New
Zealand, Pakistan, Panama, Paraguay, Peru, Romania, Singapore, Switzerland,
Taiwan, Thailand, Turkey, United Kingdom, Uruguay, and Venezuela.
Countries/jurisdictions with pending requirements include France, Guernsey,
Honduras, Malta, Norway, the Philippines, and Spain. It is worth noting that
the constitutions of these countries do not necessarily protect individual
liberties as stringently as does the United States Constitution. Proposed
Rule at 69, 525 n. 4.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> Tobacco manufacturers also criticized the "study's use of intentions
to measure behavioral change and stated that FDA should have presented data
showing actual effects on behavior." Final Rule at 36, 642. FDA disagreed
that intentions were an inappropriate variable, explaining that while
intentions do not perfectly predict future behavior, they are a "necessary
precursor." <i><cite>Id</cite>.</i> FDA also cites the "scientific literature['s]" shocking
conclusion "that one's intentions to quit smoking must be increased before
one makes the actual quit attempt." <i><cite>Id</cite>.</i> In response to comments raising
concerns about the lack of strong statistically significant results
concerning intention, FDA explained that although <i>its</i> study made no attempt
to show that increased intention to quit translated to actual (let alone
successful) quit attempts, "the overall body of scientific literature"
provides sufficient evidence that the warnings, "by increasing public
understanding of and thoughts about the health risks of smoking, will be
effective in encouraging smoking cessation and discouraging smoking
initiation." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> The question here is whether the graphic warnings actually <i>do</i>
constitute the type of disclosure requirements that are reviewable under
<i>Zauderer's</i> relaxed standard" &mdash; what the dissent characterizes as "attempts
only to prescribe what shall be orthodox in commercial advertising," Dissent
at 1226 (quoting <i>Zauderer v. Office of Disciplinary Counsel</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. 626</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=85%20l%20ed%202d%20652&amp;summary=yes#jcite">85 L.Ed.2d 652</a> (1985)) &mdash; or whether they are more akin
to attempts to "prescribe what shall be orthodox in . . . matters of
opinion," <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>, as the Companies
contend. The dissent overlooks the element of compulsion, which at least
creates an argument in favor of applying strict scrutiny.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> FDA, <i>Tobacco Strategy Announcement</i> (Nov. 10, 2010), <i>available at</i>
http://www.fda.gov/TobaccoProducts/NewsEvents/ucm232556.htm; <i>see also</i> Press
Briefing by Press Secretary Jay Carney, Health and Human Services Secretary
Kathleen Sebelius, and FDA Commissioner Margaret Hamburg (June 21, 2011),
<i>available at</i>
http://www.whitehouse.gov/the-press-office/2011/06/21/press-briefing-press-secretary-jay-carney-secretary-health-and-human-ser.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Justice Souter noted that, although it was not cited by the government
in <i>Glickman, Zauderer</i> represented "the closest pass at authority for his
limited rationale of commercial speech protection" because it was "our only
examination of a commercial-speech mandate before today." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCUO?jcsearch=521%20us%20457&amp;summary=yes#jcite">521 U.S. at 490</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=117%20supreme%20court%202130&amp;summary=yes#jcite">117 S.Ct. 2130</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> The dissent also claims that the government has provided "more than
sufficient evidence that cigarette packages and other advertisements remain
likely to mislead consumers notwithstanding the existing warnings." Dissent
at 1228. In the Final Rule, the FDA found that consumers are uninformed
about "the nature and extent of the health risks associated with smoking
cigarettes," Final Rule at 36, 632, such as "the severity and magnitude" of
those risks, their personal risks, the effects of secondhand smoke, and the
highly addictive nature of cigarettes. <i>See </i><cite>id. at 36</cite>, 632-33. But none of
the proposed warnings purport to address the information gaps identified by
the government.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> To the extent that there is a concern about the Companies' past
deception, the Act precludes them from "portray[ing] the use of tobacco as .
. . healthful to minors," <i>see</i> Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(17)&amp;summary=yes#jcite">&sect; 2(17)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=123%20stat%201776&amp;summary=yes#jcite">123 Stat, at 1778</a>, by precluding
the Companies from using "light" and other descriptors. <i>See</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HBU003?jcsearch=21%20usc%20387k&amp;summary=yes#jcite">21 U.S.C. &sect; 387k</a>.
And Congress's objection to the Companies' portrayal of smoking as "socially
acceptable" is likewise remedied by the constraints of the Act.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> Such matters are the subject of a pending &mdash; and entirely separate &mdash;
line of litigation against the Companies. <i>See Philip Morris USA Inc.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d 1095</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> <i>Central Hudson</i> also provides that commercial speech only receives
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment protection if it is a lawful activity and is not misleading
or fraudulent. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. Neither party seriously
disputes that the cigarette packaging and advertisements regulated by the
Act satisfy this threshold requirement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Moreover, the Institute of Medicine Report, on which FDA relies for
some of its evidence supporting the Rule, states unequivocally that "the
primary objective of tobacco regulation is not to promote informed choice
but rather to discourage consumption of tobacco products . . . as a means of
reducing tobacco-related death and disease." Institute of Medicine, <i>Ending</i>
<i>the Tobacco Problem: A Blueprint for the Nation</i> 291 (2007), <i>available at</i>
http://www.nap.edu/catalog.phpPrecord_<cite>id</cite>=11795. The Report goes on to state
that "[e]ven though tobacco products are legally available to adults, the
paramount public health aim is to reduce the number of people who use and
become addicted to these products, through a focus on children and youths,"
and recommends that the "warnings must be designed to promote this
objective." <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> Like the district court, we are skeptical that the government can
assert a substantial interest in discouraging consumers from purchasing a
lawful product, even one that has been conclusively linked to adverse health
consequences. Nonetheless, the Supreme Court has at least implied that the
government could have a substantial interest in reducing smoking rates
because smoking poses "perhaps the single most significant threat to public
health in the United States." <i>FDA v. Brown &amp; Williamson Tobacco Corp.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. 120</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">161</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=146%20l%20ed%202d%20121&amp;summary=yes#jcite">146 L.Ed.2d 121</a> (2000).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> Such an analysis is required under Executive Order 12866,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5421SSD46PP082G8H?jcsearch=58%20federal%20register%2051&amp;summary=yes#jcite">58 Fed.Reg. 51</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=58%20federal%20register%2051&amp;summary=yes#jcite">735</a> (Sept. 30, 1993), which directs agencies to assess all
costs and benefits of available regulatory alternatives and, when regulation
is necessary, to select the approach that maximizes net benefits.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1500" name="fn1500">[fn15]</a></span> FDA also urges us to defer to Congress's judgment regarding the
efficacy of the graphic warnings. <i>See Turner Broad. Sys., Inc. v. FCC</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCSH?jcsearch=520%20us%20180&amp;summary=yes#jcite">520 U.S. 180</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCSH?jcsearch=520%20us%20180&amp;summary=yes#jcite">196</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=117%20supreme%20court%201174&amp;summary=yes#jcite">117 S.Ct. 1174</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCSH?jcsearch=137%20l%20ed%202d%20369&amp;summary=yes#jcite">137 L.Ed.2d 369</a> (1997). But deference is
only warranted where Congress "base[s] its conclusions upon substantial
evidence," <i>id.</i>, and Congress's predictive judgments are not "insulated from
meaningful judicial review." <i>Turner</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCKG?jcsearch=512%20us%20622&amp;summary=yes#jcite">512 U.S. at 666</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=114%20supreme%20court%202445&amp;summary=yes#jcite">114 S.Ct. 2445</a>.
Deference is not appropriate here, because we find little evidence showing
that the graphic warnings will advance the stated purpose of the statute &mdash;
"promot[ing] cessation to reduce disease risk and the social costs
associated with tobacco-related diseases." Act. <cite>&sect; 3.9</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1600" name="fn1600">[fn16]</a></span> The dissent accuses us of "choosing to ignore" this interest, thereby
ignoring our explanation that the government's stated interest in
"effectively" communicating information is illusory absent some barometer
for assessing that effectiveness.
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  ROGERS, Circuit Judge, dissenting:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The threshold question in this government appeal is whether the district
court applied the correct level of scrutiny in addressing the tobacco
companies' <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment challenge to the requirement that they <span CLASS="page_no" data-cite="2012 bl 217700 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> disclose
the negative health consequences of smoking on cigarette packages and other
advertisements.<a HREF="#fn101" name="fnref_fn101">[fn1]</a> The speech at issue &mdash; proposing the sale of cigarettes
&mdash; is indisputably commercial speech. Consequently, contrary to the district
court's application of strict scrutiny, the question is whether, under the
traditional standards adopted by the Supreme Court, the government's warning
label requirement is subject to the "less exacting scrutiny" of <i>Zauderer v.</i>
<i>Office of Disciplinary Counsel of the Supreme Court of Ohio</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBAS?jcsearch=477%20us%20626&amp;summary=yes#jcite">477 U.S. 626</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=477%20us%20626&amp;summary=yes#jcite">650-51</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=85%20l%20ed%202d%20652&amp;summary=yes#jcite">85 L.Ed.2d 652</a> (1985), or to intermediate scrutiny
under <i>Central Hudson Gas &amp; Electric Corp. v. Public Service Commission of</i>
<i>New York</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. 557</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=65%20l%20ed%202d%20341&amp;summary=yes#jcite">65 L.Ed.2d 341</a> (1980). In
affirming the grant of summary judgment to the tobacco companies, the court
applies the wrong level of scrutiny, disregarding the tobacco companies'
history of deceptive advertising and the government's stated "primary goal,
which is to effectively convey the negative health consequences of smoking
on cigarette packages and in advertisements," Required Warnings for
Cigarette Packages and Advertisements, 76 Fed.Reg. 36, 628, 36, 633 (June
22, 2011) ("Final Rule").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the warning labels present factually accurate information and
address misleading commercial speech, as defined in Supreme Court precedent,
<i>Zauderer</i> scrutiny applies, and the government need
<span CLASS="page_no" data-cite="402 us appeals dc 456" data-cite-type="SecondaryFederalReporter" data-cite-pageno="456" data-primary-citation="402 U.S. App. D.C. 438">[**456]</span> <span CLASS="page_no" data-cite="696 f 3d 1223" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1223" data-primary-citation="696 F.3d 1205">[*1223]</span> 
show only that the warning label requirement is reasonably related to its
stated and substantial interest in effectively conveying this information to
consumers. <i>See Milavetz, Gallop &amp; Milavetz, P.A. v. United States</i>,
<cite>___ U.S. ___</cite>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. 1324</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">1339-40</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=176%20l%20ed%202d%2079&amp;summary=yes#jcite">176 L.Ed.2d 79</a> (2010); <i>Zauderer</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 650-51</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>Spirit Airlines, Inc. v. U.S. Dep't of</i>
<i>Transp.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=687%20f%203d%20403&amp;summary=yes#jcite">687 F.3d 403</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=687%20f%203d%20403&amp;summary=yes#jcite">412</a> (D.C.Cir.2012). Even treating <i>Zauderer's</i> less
exacting scrutiny" as limited to disclosure requirements serving a
governmental interest in preventing consumer deception, the voluminous
findings of our own courts, cited and supplemented by Congress in the Family
Smoking Prevention and Tobacco Control Act ("Tobacco Control Act" or "Act"),
Pub.L. No. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USACTS%20111-31&amp;summary=yes#jcite">111-31</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=123%20Stat.%201776&amp;summary=yes#jcite">123 Stat. 1776</a> (2009), and the Federal Drug
Administration ("FDA") in the Final Rule, are more than adequate to
substantiate that interest.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Regardless of which level of scrutiny applies, the court errs in failing
to examine both of the government's stated interests. In the rulemaking,
the, FDA articulated complementary, but distinct, interests in effectively
conveying information about the negative health consequences of smoking to
consumers and in decreasing smoking rates. <i>See, e.g.</i>, Final Rule,
76 Fed.Reg. at 36, 633. The court dismisses the former interest as "too
vague," Maj. Op. at 1221, thereby sidestepping much of the substantial
evidence supporting the warning label requirement. Yet this court has
"recognize[d] that the government's interest in preventing consumer
fraud/confusion may well take on added importance in the context of a
product . . . that can affect the public's health." <i>Pearson v. Shalala</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">164 F.3d 650</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">656</a> (D.C.Cir.1999). Tobacco products necessarily affect the
public health, and to a significant degree. Unlike other consumer products,
"tobacco products are 'dangerous to health' when used in the manner
prescribed." <i>FDA v. Brown &amp; Williamson <span CLASS="page_no" data-cite="2012 bl 217700 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> Tobacco Corp.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. 120</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">135</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=146%20l%20ed%202d%20121&amp;summary=yes#jcite">146 L.Ed.2d 121</a> (2000). They are also highly addictive.
Consequently, "tobacco use, particularly among children and adolescents,
poses perhaps the single most significant threat to public health in the
United States." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20U.S.%20120&amp;summary=yes#jcite">Id. at 161</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>. Thus, the government's
informational interest "take[s] on added importance," <i>Pearson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">164 F.3d at 656</a>, and merits independent consideration. Upon consideration of
this interest, the government appears to have met its burden under <i>Central</i>
<i>Hudson</i> as well as <i>Zauderer</i>, except with regard to the additional inclusion
of the "<cite>1-800-QUIT-NOW</cite>" number in each label.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Accordingly, because the district court erred in applying strict scrutiny
to the commercial disclosures at issue, and because those disclosures,
except as discussed below, appear to survive either level of scrutiny under
traditional commercial speech precedent, I would reverse the grant of
summary judgment, and I respectfully dissent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>I.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The context of the challenged warning label requirement can be summarized
briefly. First, it is beyond dispute that the textual statements in the
warning labels required under the Tobacco Control Act convey factually
accurate information. Tobacco use is the leading preventable cause of death
in the United States. It causes or contributes to at least sixteen kinds of
cancer, as well as heart and cerebrovascular disease, chronic bronchitis,
and emphysema, thereby "kill[ing] more than 400,000 Americans every year &mdash;
more deaths than from AIDS, alcohol, car accidents, murders, suicides,
drugs, and fires, combined." President's Cancer Panel, <i>Promoting Healthy</i>
<i>Lifestyles</i> 61 (2007)
<span CLASS="page_no" data-cite="402 us appeals dc 457" data-cite-type="SecondaryFederalReporter" data-cite-pageno="457" data-primary-citation="402 U.S. App. D.C. 438">[**457]</span> <span CLASS="page_no" data-cite="696 f 3d 1224" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1224" data-primary-citation="696 F.3d 1205">[*1224]</span> 
(hereinafter "PCP Report"); <i>see </i><cite>id. at 61-62</cite>. The nicotine contained in
tobacco is "one of the most addictive substances used by humans." Institute
of Medicine, <i>Ending the Tobacco Problem: A Blueprint for the Nation</i> 5 (2007)
(hereinafter "IOM Report"). Despite increasing public awareness that smoking
is dangerous to one's health, most people still lack "a complete
understanding of the many serious diseases caused by smoking, the true
nature of addiction, or what it would be like to experience either those
diseases or addiction itself." <i>United States v. Philip Morris USA Inc.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X8RELON?jcsearch=449%20f%20supp%202d%201&amp;summary=yes#jcite">449 F.Supp.2d 1</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X8RELON?jcsearch=449%20f%20supp%202d%201&amp;summary=yes#jcite">578</a> (D.D.C.2006). Adolescents in particular tend "to
underestimate or be uninformed about the difficulty of stopping smoking,"
IOM Report at E-8; as a result, "they are less likely to believe that the
risk of addiction and related health consequences apply to them," <i><cite>id</cite>.</i> at
E-13. Over eighty percent of adult smokers became addicted to tobacco at or
below the age of eighteen; of these smokers, half will die prematurely from
a tobacco-related disease. PCP Report at 64. In view of these facts, the
Supreme Court has recognized that "tobacco use, particularly among children
and adolescents, poses perhaps the single most significant threat to public
health in the United States." <i>Brown &amp; Williamson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. at 161</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, it is also beyond dispute that the tobacco companies have engaged
in a decades-long campaign to deceive consumers about these facts. Despite
knowledge of "the negative health consequences of smoking, the addictiveness
<span CLASS="page_no" data-cite="2012 bl 217700 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> and manipulation of nicotine, [and] the harmfulness of secondhand smoke,"
tobacco company executives "made, caused to be made, and approved public
statements contrary to this knowledge." <i>United States v. Philip Morris USA</i>
<i>Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d 1095</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">1121</a> (D.C.Cir.2009). Specifically, they "publicly
denied and distorted the truth about the addictive nature of their products,
suppressed research revealing the addictiveness of nicotine, and denied
their efforts to control nicotine levels and delivery," all while
"engineer[ing] their products around creating and sustaining [nicotine]
addiction." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20F.3d%201095&amp;summary=yes#jcite">Id. at 1107</a>. The tobacco company executives "knew of the[]
falsity" of their statements "at the time" and "made the statements with the
intent to deceive." <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20F.3d%201095&amp;summary=yes#jcite">Id. at 1124</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Beginning in 1965, the government undertook to warn consumers of the
health risks associated with smoking by requiring the inclusion of a health
warning on the side of cigarette packages. <i>See</i> Federal Cigarette Labeling
and Advertising Act of 1965, Pub.L. No. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USACTS%2089-92&amp;summary=yes#jcite">89-92</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=79%20Stat.%20282&amp;summary=yes#jcite">79 Stat. 282</a> (1965). Congress
last revised the content and format of these warning labels in 1984. <i>See</i>
Comprehensive Smoking Education Act of 1984, Pub.L. No. <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USACTS%2098-474&amp;summary=yes#jcite">98-474</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=98%20stat%202200&amp;summary=yes#jcite">98 Stat. 2200</a> (1984). Since then, "evidence regarding the ineffectiveness of
the prescribed warnings has continued to accumulate," supporting the
conclusion that these warnings "are unnoticed and stale, and they fail to
convey relevant information in an effective way." IOM Report at 291.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In view of this background, in 2009 Congress enacted the Tobacco Control
Act. Congress found that "[a] consensus exists within the scientific and
medical communities that tobacco products are inherently dangerous and cause
cancer, heart disease, and other serious adverse health effects," and that
"[n]icotine is an addictive drug." Tobacco Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(2)&amp;summary=yes#jcite">&sect; 2(2)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(3)&amp;summary=yes#jcite">(3)</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=123%20stat%201776&amp;summary=yes#jcite">123 Stat. at 1777</a> (codified at <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a> Note (2011)). Additionally,
Congress found that in 2005 the tobacco companies "spent more than $13
[billion] to attract new users, retain current users, increase current
consumption, and generate favorable long-term attitudes toward smoking and
tobacco use," <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(16)&amp;summary=yes#jcite">id. &sect; 2(16)</a>, "often misleadingly
<span CLASS="page_no" data-cite="402 us appeals dc 458" data-cite-type="SecondaryFederalReporter" data-cite-pageno="458" data-primary-citation="402 U.S. App. D.C. 438">[**458]</span> <span CLASS="page_no" data-cite="696 f 3d 1225" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1225" data-primary-citation="696 F.3d 1205">[*1225]</span> 
portray[ing] the use of tobacco as socially acceptable and healthful to
minors," <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(17)&amp;summary=yes#jcite">id. &sect; 2(17)</a>. Based on these and other findings, Congress required,
as relevant, the rotating display of one of nine textual warnings,<a HREF="#fn201" name="fnref_fn201">[fn2]</a>
accompanied by "color graphics depicting the negative health consequences of
smoking" to be selected by the Secretary of Health and Human Services, on
cigarette packages and other advertisements. Tobacco Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333(a)&amp;summary=yes#jcite">&sect; 201(a)</a>,
<cite>123 Stat, at 1842-45</cite> (codified at <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=15%20usc%201333&amp;summary=yes#jcite">15 U.S.C. &sect; 1333</a> Note (2011)) (hereinafter
"<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333&amp;summary=yes#jcite">Section 201</a>"). These requirements become effective fifteen months from the
issuance of the implementing regulations. <i>See </i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333(b)&amp;summary=yes#jcite">id. &sect; 201(b)</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the Final Rule, the FDA, acting on behalf of the Secretary,<a HREF="#fn301" name="fnref_fn301">[fn3]</a> stated
that its "primary goal" in selecting the graphic images pursuant to <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333&amp;summary=yes#jcite">Section
201</a> was "to effectively convey the negative health consequences of smoking
on cigarette packages and in advertisements." Final Rule, 76 Fed.Reg. at 36,
633; <i>see also </i><cite>id. at 36</cite>, 641. The FDA also explained that "this effective
communication can help both to discourage nonsmokers, including <span CLASS="page_no" data-cite="2012 bl 217700 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> minor
children, from initiating cigarette use and to encourage current smokers to
consider cessation to greatly reduce the serious risks that smoking poses to
their health." <i>See <cite>id</cite>.; see also </i><cite>id. at 36</cite>, 640. In selecting nine of the
thirty-six graphic images presented in the proposed rule, <i>see</i> Required
Warnings for Cigarette Packages and Advertisements, 75 Fed.Reg. 69, 524
(proposed Nov. 12, 2010) ("Proposed Rule"), the FDA relied on the results of
a consumer study conducted, in part, "to quantitatively evaluate the
[relative] efficacy of the proposed required warnings in communicating the
health harms of smoking to adults . . ., young adults . . ., and youth"
("FDA study"). Final Rule, 76 Fed.Reg. at 36, 635; <i>see </i><cite>id. at 36</cite>, 637-39. In
particular, the FDA focused on the salience measures reported for each of
the thirty-six graphic images considered in the study; these measures
included "[e]motional reactions, cognitive reactions, and [reactions as to]
whether the warning was difficult to look at." <i></i><cite>Id. at 36</cite>, 696. Echoing the
Institute of Medicine in justifying its reliance on these measures, the use
of which "is well-established in the scientific literature," <i></i><cite>id. at 36</cite>,
696-97, the FDA explained that "the literature suggests that risk
information is most readily communicated by messages that arouse emotional
reactions, and that smokers who report greater negative emotional reactions
in response to cigarette warnings are significantly more likely to have read
and thought about the warnings. . . ." <i></i><cite>Id. at 36</cite>, 639; <i>see</i> IOM Report at
C-3. After considering the results of the FDA study "and a number of other
factors," the FDA "concluded that the nine selected required warnings
effectively communicate the negative health consequences of smoking." <i></i><cite>Id. at
36</cite>, 637.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>II.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Because the degree of protection afforded by the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment depends
<span CLASS="page_no" data-cite="696 f 3d 1226" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1226" data-primary-citation="696 F.3d 1205">[*1226]</span> 
<span CLASS="page_no" data-cite="402 us appeals dc 459" data-cite-type="SecondaryFederalReporter" data-cite-pageno="459" data-primary-citation="402 U.S. App. D.C. 438">[**459]</span> on whether the activity sought to be regulated constitutes commercial or
noncommercial speech, we must <i>first</i> determine the proper classification of
the [speech] at issue here." <i>Bolger v. Youngs Drug Prods. Corp.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CAN7?jcsearch=463%20us%2060&amp;summary=yes#jcite">463 U.S. 60</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CAN7?jcsearch=463%20us%2060&amp;summary=yes#jcite">65</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=103%20supreme%20court%202875&amp;summary=yes#jcite">103 S.Ct. 2875</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CAN7?jcsearch=77%20l%20ed%202d%20469&amp;summary=yes#jcite">77 L.Ed.2d 469</a> (1983) (emphasis added).
Recognizing "the 'commonsense' distinction between speech proposing a
commercial transaction, which occurs in an area traditionally subject to
government regulation, and other varieties of speech," the Supreme Court has
repeatedly instructed that the "Constitution . . . accords a lesser
protection to commercial speech than to other constitutionally guaranteed
expression," <i>Central Hudson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 562-63</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a> (citations
and internal quotation marks omitted).<a HREF="#fn401" name="fnref_fn401">[fn4]</a> The Court has reasserted this
"commonsense" distinction in the context of compelled speech,
differentiating between attempts to "prescribe what shall be orthodox in
politics, nationalism, religion, or other matters of opinion or force
citizens to confess by word or act their faith therein" and attempts "only
to prescribe what shall be orthodox in commercial advertising." <i>Zauderer</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a> (citations and internal quotation marks
omitted).<a HREF="#fn501" name="fnref_fn501">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Indeed, in view of "material differences between disclosure requirements
and outright prohibitions on speech," <i></i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20U.S.%20at%20651&amp;summary=yes#jcite">id. at 650</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>, the
Supreme Court has taken this distinction a step further. Whereas <span CLASS="page_no" data-cite="2012 bl 217700 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> in the
context of noncommercial speech, "compulsion to speak may be as
<span CLASS="page_no" data-cite="402 us appeals dc 460" data-cite-type="SecondaryFederalReporter" data-cite-pageno="460" data-primary-citation="402 U.S. App. D.C. 438">[**460]</span> <span CLASS="page_no" data-cite="696 f 3d 1227" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1227" data-primary-citation="696 F.3d 1205">[*1227]</span> 
violative of the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment as prohibitions on speech" and thus trigger
the same level of scrutiny, <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20U.S.%20at%20651&amp;summary=yes#jcite">id</a>.</i>, in the context of commercial speech,
compulsion to speak may be <i>less</i> violative of the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment than
prohibitions on speech and thus trigger a <i>lower</i> level of scrutiny, <i>see id.</i>
at 650-51, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>. "Because the extension of <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment
protection to commercial speech is justified principally by the value to
consumers of the information such speech provides," the Court explained,
"disclosure requirements trench much more narrowly on an advertiser's
interests than do flat prohibitions on speech. . . ." <i>Id.</i> at 651,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a> (citations omitted); <i>see </i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20U.S.%20at%20651&amp;summary=yes#jcite">id. at 651</a> n. 14, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>;
<i>Va. Bd. of Pharmacy v. Va. Citizens Consumer Council, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">425 U.S. 748</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C951?jcsearch=425%20us%20748&amp;summary=yes#jcite">770</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=96%20supreme%20court%201817&amp;summary=yes#jcite">96 S.Ct. 1817</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C951?jcsearch=48%20l%20ed%202d%20346&amp;summary=yes#jcite">48 L.Ed.2d 346</a> (1976). Consequently, while "unjustified
or unduly burdensome disclosure requirements might offend the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a>
Amendment by chilling protected commercial speech[,] . . . an advertiser's
rights are adequately protected as long as disclosure requirements are
reasonably related to the State's interest in preventing deception of
consumers." <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>see Milavetz</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339-40</a>.<a HREF="#fn601" name="fnref_fn601">[fn6]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the Supreme Court explained in <i>Milavetz</i>, where the challenged
requirements are "directed at <i>misleading</i> commercial speech," and where they
"impose a disclosure requirement rather than an affirmative limitation on
speech, . . . the less exacting scrutiny described in <i>Zauderer</i> governs [a
court's] review." <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339</a>; <i>see Spirit Airlines</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1I0TMG003?jcsearch=687%20f%203d%20403&amp;summary=yes#jcite">687 F.3d at 412</a>.
The warning label requirement meets both of these criteria.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  First, the government need show only that the targeted commercial speech
presents the "possibility of deception" or a "tendency to mislead."
<i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a> (citation and internal quotation marks omitted).
If the speech is actually misleading, it enjoys no <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment
protection. <i>See Thompson v. W. States Med. Ctr.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. 357</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">367</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=152%20l%20ed%202d%20563&amp;summary=yes#jcite">152 L.Ed.2d 563</a> (2002); <i>Central Hudson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. Where "the likelihood of deception" is "hardly a speculative
one," the government need not produce "evidence that [the] advertisements
are misleading," as the court may rely instead on experience and common
sense. <i>Spirit Airlines</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1I0TMG003?jcsearch=687%20f%203d%20403&amp;summary=yes#jcite">687 F.3d at 413</a> (alteration in original) (quoting
<i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>) (internal quotation marks omitted). In
<i>Milavetz</i>, the Supreme Court concluded that a law firm's advertisements were
"inherently misleading" because they "promise[d] . . . debt relief without
any reference to the possibility of filing for bankruptcy, which has
inherent costs." <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>. Thus, absent any additional
evidence, the Court considered the omission of a reference to a possible
outcome with "inherent costs" to be sufficiently misleading as to warrant
review under <i>Zauderer.</i> Even advertisements that display all the costs of a
service may remain misleading. In <i>Spirit Airlines<span CLASS="page_no" data-cite="402 us appeals dc 461" data-cite-type="SecondaryFederalReporter" data-cite-pageno="461" data-primary-citation="402 U.S. App. D.C. 438">[**461]</span> </i>,
<span CLASS="page_no" data-cite="696 f 3d 1228" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1228" data-primary-citation="696 F.3d 1205">[*1228]</span> 
this court addressed a Department of Transportation ("DOT") rule requiring
that the most prominent number displayed in airfare advertisements be the
total price, inclusive of taxes. <i>Spirit Airlines</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1I0TMG003?jcsearch=687%20f%203d%20403&amp;summary=yes#jcite">687 F.3d at 408-09</a>.
Notwithstanding the airlines' compliance with preexisting regulations
requiring advertisements to display the entire ticket cost as <span CLASS="page_no" data-cite="2012 bl 217700 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> well as the
amount of any tax, the court accepted DOT's determination, based on common
sense and experience, "that it was deceitful and misleading when the most
prominent price listed by an airline is anything other than the total, final
price of air travel." <i>Id.</i> at 413. Accordingly, the court proceeded to review
the rule under <i>Zauderer. See id.</i> at 413-14.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even absent any affirmatively misleading statements, <i>see</i> Maj. Op. at
1214-15, cigarette packages and other advertisements that fail to display
the final costs of smoking in a prominent manner are at least as misleading
as the airline advertisements in <i>Spirit Airlines.</i> Existing warnings, last
revised in 1984, appear on one side panel and occupy only four percent of
cigarette packages. <i>See</i> Final Rule, 76 Fed.Reg. at 36, 678. Common sense,
experience, and substantial scientific evidence support the conclusion that
these warnings are ineffective. "For example," in 2007 the Institute of
Medicine "concluded that U.S. package warnings are both 'unnoticed and
stale.'" Proposed Rule, 75 Reg. at 69, 530 (quoting IOM Report at 291); <i>see</i>
<i>generally id.</i> The government has thus provided more than sufficient evidence
that cigarette packages and other advertisements remain likely to mislead
consumers notwithstanding the existing warnings. <i>See Discount Tobacco City &amp;</i>
<i>Lottery v. United States</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d 509</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">562-63</a> (6th Cir.2012). Yet it goes
even further, demonstrating that these warnings actually "have failed to
convey appropriately crucial information such as the nature and extent of
the health risks associated with smoking cigarettes." Final Rule,
76 Fed.Reg. at 36, 632; <i>see</i> Proposed Rule, 75 Fed.Reg. at 69, 530-31 (citing
studies); <i>see also Discount Tobacco</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d at 563-64</a>. Even though "most
smokers understand that smoking poses certain statistical risks to their
health," studies noted by the FDA show that "many fail to appreciate the
severity and magnitude of those risks." Final Rule, 76 Fed.Reg. at 36, 632.
Moreover, "many smokers underestimate their personal risks." <i><cite>Id</cite>.</i> (noting,
for example, studies in which only a minority of smokers believed they were
at increased risk for cancer and heart disease). Many people are also
unaware of the effects of secondhand smoke on others. <i>See </i><cite>id. at 36</cite>, 633.
And adolescents in particular fail to appreciate the highly addictive nature
of cigarettes. <i>See <cite>id</cite>.; see also Philip Morns</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X8RELON?jcsearch=449%20f%20supp%202d%201&amp;summary=yes#jcite">449 F.Supp.2d at 578</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, even if (contrary to Supreme Court and this court's
precedent) these findings were inadequate to establish a "tendency to
mislead," this court has recognized that certain advertisements, "although
not misleading if taken alone," can "become[] misleading" when "considered
in light of past advertisements." <i>Warner-Lambert Co. v. FTC</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20f%202d%20749&amp;summary=yes#jcite">562 F.2d 749</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20f%202d%20749&amp;summary=yes#jcite">760</a> (D.C.Cir.1977); <i>see <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20F.2d%20749&amp;summary=yes#jcite">id</a>.</i> at n. 57.<span CLASS="page_no" data-cite="402 us appeals dc 462" data-cite-type="SecondaryFederalReporter" data-cite-pageno="462" data-primary-citation="402 U.S. App. D.C. 438">[**462]</span> <a HREF="#fn701" name="fnref_fn701">[fn7]</a>
<span CLASS="page_no" data-cite="696 f 3d 1229" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1229" data-primary-citation="696 F.3d 1205">[*1229]</span> 
In other words, a "tendency to mislead" may arise through efforts to
"capitalize on . . . prior deceptions by continuing to advertise in a manner
that builds on consumers' existing misperceptions." <i>Philip Morris</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1144-45</a> (citing <i>Warner-Lambert</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3OP7P?jcsearch=562%20f%202d%20749&amp;summary=yes#jcite">562 F.2d at 769</a>). This court has
already acknowledged the tendency of cigarette marketing to mislead
consumers based on the companies' decades of deception regarding each of the
risks identified in the warning labels. <i>See Philip Morris</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1144</a>;
<i><cite>supra</cite></i> Part I.<a HREF="#fn801" name="fnref_fn801">[fn8]</a> Consistent <span CLASS="page_no" data-cite="2012 bl 217700 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> with that decision, Congress found that
"[t]obacco product advertising often misleadingly portrays the use of
tobacco as socially acceptable and healthful to minors." Tobacco Control Act
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(17)&amp;summary=yes#jcite">&sect; 2(17)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a> Note. These findings are more than "adequate to
establish that the likelihood of deception in this case 'is hardly a
speculative one.'" <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340</a>; <i>see Discount Tobacco</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d at 562</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Second, the warning label requirement does not impose "an affirmative
limitation on speech," <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339</a>; rather, the warning
labels disclose information about the negative health consequences of
smoking. (The one exception is discussed <i>infra.</i>) Unlike other provisions of
the Tobacco Control Act, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333&amp;summary=yes#jcite">Section 201</a> does not restrict the information
conveyed to consumers, but requires additional information to be conveyed
with the aid of graphic images. Although the tobacco companies object that
the warnings "monopolize all the prominent space on cigarette packages, and
thereby make it impossible for manufacturers to communicate their own
messages and their own view-points <i>prominently</i> in packaging," Joint Comments
of R.J. Reynolds Tobacco Co., Lorillard Tobacco Co. &amp; Commonwealth Brands,
Inc. 9 (Jan. 11, 2010) (J.A. 216) (emphasis added), their objection rings
hollow in the absence of <i>any</i> evidence of difficulty in conveying their
desired messages notwithstanding a decade of experience under a similar
warning label requirement in Canada. <i>See</i> Final Rule, 76 Fed.Reg. at 36, 633,
36, 698; Appellants' Br. at Add. 6-12; <i>cf. Ibanez v. Flo. Dep't Bus. &amp; Profl</i>
<i>Regulation</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=512%20us%20136&amp;summary=yes#jcite">512 U.S. 136</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=512%20us%20136&amp;summary=yes#jcite">146-47</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=114%20supreme%20court%202084&amp;summary=yes#jcite">114 S.Ct. 2084</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVH7?jcsearch=129%20l%20ed%202d%20118&amp;summary=yes#jcite">129 L.Ed.2d 118</a> (1994).
Consequently, they fail to show that the warning label requirement is "an
affirmative limitation on speech." <i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339</a>; <i>see Spirit</i>
<i>Airlines</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1I0TMG003?jcsearch=687%20f%203d%20403&amp;summary=yes#jcite">687 F.3d at 413-14</a>. To the extent the warning labels disclose
factually accurate information about the cigarettes being advertised, then,
<i>Zauderer</i> offers the appropriate level of scrutiny.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The tobacco companies do not challenge the factual accuracy of the textual
statements included in the warning labels. <i>See</i> Appellees' Br. at 54-55. Nor
could they reasonably do so, given the scientific consensus "that tobacco
products are inherently dangerous and cause cancer, heart disease, and other
serious adverse health
<span CLASS="page_no" data-cite="402 us appeals dc 463" data-cite-type="SecondaryFederalReporter" data-cite-pageno="463" data-primary-citation="402 U.S. App. D.C. 438">[**463]</span> <span CLASS="page_no" data-cite="696 f 3d 1230" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1230" data-primary-citation="696 F.3d 1205">[*1230]</span> 
effects." Tobacco Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(2)&amp;summary=yes#jcite">&sect; 2(2)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a> Note; <i>see</i> Final Rule,
76 Fed.Reg. at 36, 641; Proposed Rule, 75 Fed.Reg. at 69, 527-29. The
question for purposes of the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment analysis, then, is whether the
graphic images selected by the FDA to accompany the factually accurate
textual statements render the warnings nonfactual or controversial. To
answer this question, the court must &mdash; although the court does not, <i>see</i> Maj.
Op. at 1216-17 &mdash; view the images in connection with the textual warnings
they accompany. <i>See, e.g., S. Air Transp., Inc. v. Am. Broad. Cos., Inc.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X46C00?jcsearch=877%20f%202d%201010&amp;summary=yes#jcite">877 F.2d 1010</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X46C00?jcsearch=877%20f%202d%201010&amp;summary=yes#jcite">1015</a> (D.C.Cir.1989).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Contrary to the tobacco companies' suggestion, <i>see</i> Appellees' Br. at 24,
the use of graphic images, even if digitally enhanced, illustrated, or
symbolic, does not necessarily make the warnings nonfactual. The Supreme
Court recognized in <i>Zauderer</i> that "[t]he use of illustrations or pictures in
advertisements serves important communicative functions: it attracts the
attention of the audience to the advertiser'<span CLASS="page_no" data-cite="2012 bl 217700 p 23" data-cite-type="Bloomberg" data-cite-pageno="23" data-primary-citation="">[***23]</span> s message, and it may also serve
to impart information directly." <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBA0?jcsearch=477%20us%20626&amp;summary=yes#jcite">477 U.S. at 647</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>;
<i>see N.Y. Times Co. v. NASA</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3IJ7S?jcsearch=920%20f%202d%201002&amp;summary=yes#jcite">920 F.2d 1002</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3IJ7S?jcsearch=920%20f%202d%201002&amp;summary=yes#jcite">1005</a> (D.C.Cir.1990); <i>see, e.g.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XMI9JS003?jcsearch=16%20cfr%201500%2014&amp;summary=yes#jcite">16 C.F.R. &sect; 1500.14</a> (2011) (requiring skull-and-crossbones warnings on
poisonous products). In the Final Rule, the FDA concluded that "the effects
shown" in the images "are, in fact, accurate depictions of the effects of
sickness and disease caused by smoking," Final Rule, 76 Fed.Reg. at 36, 696,
and the tobacco companies do not suggest otherwise. That such images are not
invariably comforting to look at does not necessarily make them inaccurate.
As the FDA went on to explain the obvious fact, "the severe,
life-threatening and sometimes disfiguring health effects of smoking
conveyed in the required warnings <i>are</i> disturbing and the images [it] . . .
selected appropriately reflect this fact." Final Rule, 76 Fed.Reg. at 36,
696.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The tobacco companies further object that the graphic images were chosen
not to convey information, but to evoke negative emotions and thereby
discourage smoking. <i>See</i> Appellees' Br. at 26-27. The FDA explained, however,
that "considerable scientific evidence shows that health warnings that
elicit strong emotional and cognitive reactions," as reflected in their
salience measures, "are better processed and more effectively communicate
information about the negative health consequences of smoking." Final Rule,
76 Fed.Reg. at 36, 642; <i>see </i><cite>id. at 36</cite>, 639, 41, 46; IOM Report at C-3. Thus,
the FDA's reliance on salience measures was in the sendee of &mdash; not
inconsistent with &mdash; the warnings' informational purpose. Moreover, factually
accurate, emotive, and persuasive are not mutually exclusive descriptions;
the emotive quality of the selected images does not necessarily undermine
the warnings' factual accuracy.<a HREF="#fn901" name="fnref_fn901">[fn9]</a> Comprehending
<span CLASS="page_no" data-cite="402 us appeals dc 464" data-cite-type="SecondaryFederalReporter" data-cite-pageno="464" data-primary-citation="402 U.S. App. D.C. 438">[**464]</span> <span CLASS="page_no" data-cite="696 f 3d 1231" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1231" data-primary-citation="696 F.3d 1205">[*1231]</span> 
the facts about the actual harms resulting from smoking is likely to provoke
emotional reactions and also to discourage the use of cigarettes. <i>See</i> Final
Rule, 76 Fed.Reg. at 36, 647. The tobacco companies' argument leads to the
counterintuitive conclusion that the more concerning the negative health
effects of a particular product, the more constrained the government is in
mandating disclosures of those facts. Unsurprisingly, the tobacco companies
point neither to any case law in support of this argument nor to any legally
significant distinction between fact and emotion. See Appellees' Br. at
24-25. Rather, the greater the harms to public health, the greater the
government's interest in informing consumers of those harms. <i>See Pearson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">164 F.3d at 656</a>. This interest is especially great in view of the tobacco
companies' extensive advertising that Congress found was "often
misleading[]" and designed to attract adolescents and new users, retain and
expand consumption, and "generate favorable long-term attitudes toward
smoking and tobacco use." Tobacco Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(16)&amp;summary=yes#jcite">&sect; 2(16)</a><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(18)&amp;summary=yes#jcite">-(18)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a>
Note.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Aside from their general objections to the inclusion of graphic images for
the above reasons, the tobacco companies specifically object to five of the
nine selected images. They maintain that the images of a man smoking through
a tracheotomy hole in his throat and a man with chest staples on an autopsy
table convey misleading <span CLASS="page_no" data-cite="2012 bl 217700 p 24" data-cite-type="Bloomberg" data-cite-pageno="24" data-primary-citation="">[***24]</span> messages about the consequences of smoking, and that
the images of a man wearing a t-shirt reading "I QUIT," a baby enveloped in
smoke, and a woman crying convey no information about the consequences of
smoking whatsoever. <i>See</i> Appellees' Br. at 25-26. All of these objections
pertain to the images divorced from their accompanying text and thus fail to
address the relevant question &mdash; whether the images render the <i>overall</i>
message conveyed by the warning labels nonfactual. Viewed with the text they
accompany, none of these images has that effect.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The image accompanying the textual warning "Cigarettes are addictive"
depicts a man smoking through a tracheotomy opening in his throat. Viewed
with the accompanying text, this image conveys the tenacity of nicotine
addiction: even after under undergoing surgery for cancer, one might be
unable to abstain from smoking. Indeed, government counsel represented that
this situation is not so extreme or unusual as the court and the tobacco
companies suggest. <i>Compare</i> Oral Arg. Tr. at 57 (stating that fifty percent
of neck and head cancer patients continue to smoke) <i>with</i> Maj. Op. at
1216-17; Appellees' Br. at 25. This representation finds support from the
President's Cancer Panel. "Smoking among cancer survivors (including
individuals diagnosed with, being treated for, and surviving cancer)," the
Panel reported, "is an underappreciated and understudied problem." PCP
Report at 70. "[S]moking prevalence in this population is approximately
equivalent to people with no history of cancer," despite "mounting evidence
confirm[ing] the adverse effects of continued smoking on cancer treatment
outcomes regardless of treatment modality." <i><cite>Id</cite>.</i><a HREF="#fn1001" name="fnref_fn1001">[fn10]</a> This image thus serves
to uderline
<span CLASS="page_no" data-cite="402 us appeals dc 465" data-cite-type="SecondaryFederalReporter" data-cite-pageno="465" data-primary-citation="402 U.S. App. D.C. 438">[**465]</span> <span CLASS="page_no" data-cite="696 f 3d 1232" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1232" data-primary-citation="696 F.3d 1205">[*1232]</span> 
the factual, and now uncontroversial, statement that cigarettes are highly
addictive.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Similarly, the image of a man with staples in his chest lying on an
autopsy table works with, not against, the textual warning "Smoking can kill
you." Assuming "autopsies are not a common consequence of smoking,"
Appellees' Br. at 25, neither are coffins or gravestones; yet the status
evoked by images of an autopsy-scarred man, a coffin, or a gravestone &mdash;
death &mdash; is a common consequence of smoking. <i>See</i> Proposed Rule,
75 Fed.Reg. at 69, 526; PCP Report at 61, 64. The FDA might have opted for
an image of a decaying cadaver or of a pile of ashes to portray the likely
physical consequences of smoking, but it was not limited to such images in
its representation of those consequences. An autopsy scar is merely one way
of communicating that the man in the image is dead; viewed in connection
with the textual warning, the image conveys the message that smoking can
result in death.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The images of a baby enveloped in smoke and a woman crying both depict the
significant harms of secondhand smoke. These images accompany the textual
warnings "Tobacco smoke can harm your children" and "Tobacco smoke causes
fatal lung disease in nonsmokers," respectively. Regarding the former image,
commenters noted that it would "clearly inform parents that when they smoke
in the presence of their children, their children <span CLASS="page_no" data-cite="2012 bl 217700 p 25" data-cite-type="Bloomberg" data-cite-pageno="25" data-primary-citation="">[***25]</span> will also be inhaling
toxins." Final Rule, 76 Fed.Reg. at 36, 650. The latter image, as the FDA
explained, highlights the "emotional suffering" dimension of fatal lung
disease and other "negative health consequences caused by secondhand smoke
exposure." <i></i><cite>Id. at 36</cite>, 656. Those negative health consequences are
significant. Secondhand smoke "has been established as a cause of
approximately 3,000 lung cancer deaths each year among nonsmokers in the
United States"; it also "is a significant contributor to cardiac,
respiratory, and other diseases in individuals exposed to it." PCP Report at
95; <i>see </i><cite>id. at 95-96</cite>. As a result, secondhand smoke exposure "claims the
lives of approximately 38,000 nonsmokers annually." <i></i><cite>Id. at 95</cite>. Addressing
potential purchasers of cigarettes, these two warning labels convey the
message that smoking poses risks not only to them, but also to their family
members and others.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Initially more problematic is the image of a man wearing a t-shirt that
reads "I QUIT," which the tobacco companies maintain "provides no
information about smoking risks (or even the benefits of quitting)."
Appellees' Br. at 26. But the tobacco companies overstate the objection, for
the image does address the benefits of quitting. As the FDA viewed this
image, in connection with the textual warning "Quitting smoking now greatly
reduces serious risks to your health," it conveys the message "I quit, and I
am alive and healthy." This message comports with the evidence showing that
"[s]moking cessation decreases the risk of the health consequences of
smoking." Proposed Rule, 75 Fed.Reg. at 69, 529. "For example, persons who
quit smoking before age 50 have one-half the risk of dying in the next 15
years compared with continuing smokers." <i><cite>Id</cite>.</i> Nothing in this image, or any
other-image selected by the FDA, renders non-factual or controversial the
textual warning it accompanies. The warning labels thus qualify as factually
accurate, uncontroversial disclosures.
<span CLASS="page_no" data-cite="402 us appeals dc 466" data-cite-type="SecondaryFederalReporter" data-cite-pageno="466" data-primary-citation="402 U.S. App. D.C. 438">[**466]</span> </p></div>
<span CLASS="page_no" data-cite="696 f 3d 1233" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1233" data-primary-citation="696 F.3d 1205">[*1233]</span> <div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because the warning labels are "directed at <i>misleading</i> commercial speech,"
and because they "impose a disclosure requirement rather than an affirmative
limitation on speech, . . . the less exacting scrutiny described in
<i>Zauderer</i>" should have governed the district court's review. <i>Milavetz</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339</a>. While mindful that "unjustified or unduly burdensome
disclosure requirements might offend the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment by chilling
protected commercial speech," the district court should have determined
whether the warning label requirement was "reasonably related" to the
government's interest in effectively conveying the negative health
consequences of smoking to consumers. <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>see Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339-10</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Under this "less exacting scrutiny," the warning label requirement appears
to pass muster. The government need only justify the requirement on the
basis of substantial evidence on the record. <i>See Nat'l Cable &amp; Telecomms.</i>
<i>Ass'n v. FCC</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AIQF8003?jcsearch=555%20f%203d%20996&amp;summary=yes#jcite">555 F.3d 996</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AIQF8003?jcsearch=555%20f%203d%20996&amp;summary=yes#jcite">1002</a> (D.C.Cir.2009). In view of the scientific
literature supporting the FDA's reliance on the salience measures reported
in its study, <i>see</i> Final Rule, 76 Fed.Reg. at 36, 638, 36, 642, 36, 649-57,
the warning label requirement is reasonably related to the government's
interest in <span CLASS="page_no" data-cite="2012 bl 217700 p 26" data-cite-type="Bloomberg" data-cite-pageno="26" data-primary-citation="">[***26]</span> effectively communicating information about the negative health
consequences of smoking. And in view of extensive scientific literature, <i>see</i>
Proposed Rule, 75 Fed.Reg. at 69, 531 (citing IOM Report at C-3-4),
international experience, <i>see </i><cite>id. at 69</cite>, 531-32, domestic experience, <i>see</i>
Final Rule, 76 Fed.Reg. at 36, 632, and common sense, the size and placement
of the warning labels is also reasonably related to that interest. Although
some graphic images may evoke emotional reactions, it is undisputed that
smoking can cause the health consequences they depict. Given the magnitude
of the government interest in informing consumers of these consequences
(especially against the tobacco companies' history of consumer deception),
the expert judgment exercised by the FDA in selecting the graphic images,
and the absence of any evidence that similar restrictions else-where have
hindered the tobacco companies' ability to get their own message to
consumers, the burden on the tobacco companies' <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment rights
appears neither undue nor unjustified. The warning label requirement thus
appears constitutional. <i>See Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>cf.</i>
<i>Discount Tobacco</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d at 569</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Attempting to distinguish <i>Zauderer</i>, the court adopts the view that the
warning label requirement involves "elements of compulsion and forced
subsidization." Maj. Op. at 1211. Commercial disclosure requirements can
involve involuntary statements and compliance costs. <i>See, e.g., Milavetz</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1340-41</a>; <i>Meese v. Keene</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBDO?jcsearch=481%20us%20465&amp;summary=yes#jcite">481 U.S. 465</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBDO?jcsearch=481%20us%20465&amp;summary=yes#jcite">467</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBDO?jcsearch=481%20us%20465&amp;summary=yes#jcite">481-82</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBDO?jcsearch=107%20supreme%20court%201862&amp;summary=yes#jcite">107 S.Ct. 1862</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBDO?jcsearch=95%20l%20ed%202d%20415&amp;summary=yes#jcite">95 L.Ed.2d 415</a> (1987). Nonetheless, the Supreme Court has
reviewed such requirements under a different level of scrutiny than
noncommercial compelled speech, <i>cf. Pac. Gas &amp; Elec. Co. v. Pub. Utils.</i>
<i>Comm'n of Col.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">475 U.S. 1</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">8-9</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=106%20supreme%20court%20903&amp;summary=yes#jcite">106 S.Ct. 903</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=89%20l%20ed%202d%201&amp;summary=yes#jcite">89 L.Ed.2d 1</a> (1986), and
under a different set of considerations than compelled subsidies of private
speech, <i>cf. United States v. United Foods, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=533%20us%20405&amp;summary=yes#jcite">533 U.S. 405</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=121%20supreme%20court%202334&amp;summary=yes#jcite">121 S.Ct. 2334</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=150%20l%20ed%202d%20438&amp;summary=yes#jcite">150 L.Ed.2d 438</a> (2001). Contrary to the court's conclusion
that "this case raises novel questions about the scope of the government's
authority," Maj. Op. at 1212, given the congressional findings and
regulatory record supporting the government's interest in effectively
informing consumers of the negative, indeed potentially lethal, consequences
of smoking, the warning label requirement falls within the scope of the
Supreme Court's
<span CLASS="page_no" data-cite="402 us appeals dc 467" data-cite-type="SecondaryFederalReporter" data-cite-pageno="467" data-primary-citation="402 U.S. App. D.C. 438">[**467]</span> <span CLASS="page_no" data-cite="696 f 3d 1234" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1234" data-primary-citation="696 F.3d 1205">[*1234]</span> 
traditional <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment treatment of commercial disclosures.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Unlike the graphic images envisioned in <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333&amp;summary=yes#jcite">Section 201</a>, however, the
additional inclusion of the telephone number "<cite>1-800-QUIT-NOW</cite>" on each
warning label does not directly disclose factual information about the
health consequences of smoking. The FDA imposed this requirement, pursuant
to separate statutory authority, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HBI003?jcsearch=21%20U.S.C.%20%20387f(d)&amp;summary=yes#jcite">21 U.S.C. &sect; 387f</a>(d), <i>see</i> Final Rule,
76 Fed.Reg. at 36, 681, in order "to provide a place where smokers and other
members of the public can obtain smoking cessation information from staff
trained specifically to help smokers quit by delivering unbiased and
evidence-based information, advice, and support," Proposed Rule,
75 Fed.Reg. at 69, 540. In the FDA's view, inclusion of the number would
also enhance the effectiveness of the warning labels. See Final Rule,
76 Fed.Reg. at 36, 681. To the extent the purpose is directed toward
reducing smoking rates, the constitutionality of the number's mandatory
inclusion <span CLASS="page_no" data-cite="2012 bl 217700 p 27" data-cite-type="Bloomberg" data-cite-pageno="27" data-primary-citation="">[***27]</span> in the warning labels requires examination under a different
standard than <i>Zauderer</i>, to which I now turn.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>III.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Where <i>Zauderer</i> scrutiny is inapplicable to a commercial speech regulation,
"the Supreme Court's bottom line is clear: the government must affirmatively
demonstrate its means are 'narrowly tailored' to achieve a substantial
government goal." <i>Philip Mortis</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1143</a> (quoting <i>Bd. of Trs. v.</i>
<i>Fox</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBQI?jcsearch=492%20us%20469&amp;summary=yes#jcite">492 U.S. 469</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBQI?jcsearch=492%20us%20469&amp;summary=yes#jcite">480</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBQI?jcsearch=109%20supreme%20court%203028&amp;summary=yes#jcite">109 S.Ct. 3028</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CBQI?jcsearch=106%20l%20ed%202d%20388&amp;summary=yes#jcite">106 L.Ed.2d 388</a> (1989)); <i>see</i>
<i>Milavetz</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CQ47Q003?jcsearch=130%20supreme%20court%201324&amp;summary=yes#jcite">130 S.Ct. at 1339</a>. In applying this level of intermediate
scrutiny, the court must determine (1) whether the speech "concern[s] lawful
activity and [is] not . . . misleading," such that it enjoys <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment
protection; (2) whether the government asserts a substantial interest; (3)
"whether the regulation directly advances" that interest; and (4) whether
the regulation "is not more extensive than is necessary to serve that
interest." <i>Central Hudson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CA0A?jcsearch=447%20us%20557&amp;summary=yes#jcite">447 U.S. at 566</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>. With regard to
the third prong of this test, the Supreme Court has clarified that, although
the government "must demonstrate that the harms it recites are real and that
its restriction will in fact alleviate them to a material degree," it may do
so "by reference to studies and anecdotes pertaining to different locales
altogether, or even . . . based solely on history, consensus, and simple
common sense." <i>Lorillard Tobacco Co. v. Reilly</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. 525</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">555</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=150%20l%20ed%202d%20532&amp;summary=yes#jcite">150 L.Ed.2d 532</a> (2001) (citations and internal quotation
marks omitted). And with regard to the fourth prong, "[t]he government does
not have to show that it has adopted the least restrictive means for
bringing about its regulatory objective; it does not have to demonstrate a
perfect means &mdash; ends fit; and it does not have to satisfy a court that it
has chosen the best conceivable option." <i>Nat'l Cable</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AIQF8003?jcsearch=555%20f%203d%20996&amp;summary=yes#jcite">555 F.3d at 1002</a>. "The
only condition is that the regulation be proportionate to the interests
sought to be advanced," <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AIQF8003?jcsearch=555%20F.3d%20996&amp;summary=yes#jcite">id</a>.</i> &mdash; that there be "a reasonable fit between the
means and ends of the regulatory scheme," <i>Lorillard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. at 561</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>; <i>see </i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20U.S.%20at%20561&amp;summary=yes#jcite">id. at 556</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even assuming that the graphic images, by depicting the actual negative
consequences of cigarette smoking and thereby evoking emotional reactions,
"go beyond . . . purely factual and accurate commercial disclosures," Maj.
Op. at 1212, there would still appear, with one exception, no basis to
conclude that the warning label requirement violates the tobacco companies'
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment rights. The court reaches the opposite conclusion by
dismissing one of the two government interests stated in the rulemaking. Its
analysis is
<span CLASS="page_no" data-cite="402 us appeals dc 468" data-cite-type="SecondaryFederalReporter" data-cite-pageno="468" data-primary-citation="402 U.S. App. D.C. 438">[**468]</span> <span CLASS="page_no" data-cite="696 f 3d 1235" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1235" data-primary-citation="696 F.3d 1205">[*1235]</span> 
directed to a red herring of its own creation. Although there are statements
in the rulemaking record regarding the government's interest in reducing
smoking rates, <i>see, e.g.</i>, Final Rule, 76 Fed.Reg. at 36, 629; Proposed Rule,
75 Fed.Reg. at 69.525, nothing in that record, much less the White House
press briefing cited by the court, <i>see</i> Maj. Op. at 1212 n. 6, suggests these
statements were intended to override the clearly stated interest in
effectively communicating information about the negative health consequences
of smoking to consumers. (Nor does the Institute of Medicine's
characterization of the objectives of tobacco regulation, see Maj. Op. at
1218 n. 12, <i>detract</i> from the FDA's own statement of the government's
"primary" interest.) To the contrary, <span CLASS="page_no" data-cite="2012 bl 217700 p 28" data-cite-type="Bloomberg" data-cite-pageno="28" data-primary-citation="">[***28]</span> in the rulemaking the FDA stated
repeatedly that, "[c]onsistent with the Tobacco Control Act, the purpose of
these required warnings is to communicate effectively and graphically the
very real, scientifically established adverse health consequences of
smoking." Final Rule, 76 Fed.Reg. at 36, 641; <i>see </i><cite>id. at 36</cite>, 630, 36,
633-42, 36, 646-47, 36, 696-97, 36, 699; Proposed Rule, 75 Fed.Reg. at
69.526, 69, 531-35. Even under <i>Central Hudson</i> intermediate scrutiny, the
court should have fully examined both of the government's stated interests.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The government's informational interest in effectively conveying the
negative health consequences of smoking clearly qualifies as "substantial"
under the second prong of <i>Central Hudson.</i> "The Supreme Court has said 'there
is no question that [the government's] interest in ensuring the accuracy of
commercial information in the marketplace is substantial,'" <i>Pearson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">164 F.3d at 656</a> (quoting <i>Edenfield v. Fane</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">507 U.S. 761</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=507%20us%20761&amp;summary=yes#jcite">769</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=113%20supreme%20court%201792&amp;summary=yes#jcite">113 S.Ct. 1792</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2NVFN?jcsearch=123%20l%20ed%202d%20543&amp;summary=yes#jcite">123 L.Ed.2d 543</a> (1993)) (alteration in original), "and that
the government has a substantial interest in 'promoting the health, safety,
and welfare of its citizens,'" <i>id.</i> (quoting <i>Rubin v. Coors Brewing Co.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">514 U.S. 476</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=514%20us%20476&amp;summary=yes#jcite">485</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=115%20supreme%20court%201585&amp;summary=yes#jcite">115 S.Ct. 1585</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCMV?jcsearch=131%20l%20ed%202d%20532&amp;summary=yes#jcite">131 L.Ed.2d 532</a> (1995)). This court has
previously "recognize[d] that the government's interest in preventing
consumer fraud/confusion may well take on added importance in the context of
a product . . . that can affect the public's health." <i>Id.</i> And "tobacco use,
particularly among children and adolescents, poses perhaps the single most
significant threat to public health in the United States." <i>Brown &amp;</i>
<i>Williamson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. at 161</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>. Congress agreed. See Tobacco
Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(29)&amp;summary=yes#jcite">&sect; 2(29)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a> Note. The government interest in
effectively conveying the negative health consequences of smoking takes on
even greater importance in view of the highly addictive nature of tobacco
and the fact that "the most serious harmful consequences of smoking are
cumulative, and occur in the distant future." <i>Philip Morris</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X8RELON?jcsearch=449%20f%20supp%202d%201&amp;summary=yes#jcite">449 F.Supp.2d at 577</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The warning label requirement appears to meet the third and fourth prongs
of <i>Central Hudson</i> as well. The rulemaking record includes substantial
evidence from international experience, <i>see</i> Proposed Rule,
75 Fed.Reg. at 69, 531-32, and the FDA Study, <i>see</i> Final Rule,
76 Fed.Reg. at 36, 637-42, supporting the government's reasoned
determination that the warnings would "directly advance" its informational
interest, not least by "ensur[ing] that the health risk message[s] [are]
actually <i>seen</i> by consumers in the first instance." <i>Commonwealth Brands, Inc.</i>
<i>v. United States</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CBTPE003?jcsearch=678%20f%20supp%202d%20512&amp;summary=yes#jcite">678 F.Supp.2d 512</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1CBTPE003?jcsearch=678%20f%20supp%202d%20512&amp;summary=yes#jcite">530</a> (W.D.Ky.2010), <i>aff'd in relevant</i>
<i>part, Discount Tobacco</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d at 569</a>. "The harms [the government] recites
are real" &mdash; caused in part by the "often misleading" advertising that
smoking is part of a healthy lifestyle without consequences &mdash; and there is
substantial evidence to support the government's conclusion that the warning
label requirement
<span CLASS="page_no" data-cite="402 us appeals dc 469" data-cite-type="SecondaryFederalReporter" data-cite-pageno="469" data-primary-citation="402 U.S. App. D.C. 438">[**469]</span> <span CLASS="page_no" data-cite="696 f 3d 1236" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1236" data-primary-citation="696 F.3d 1205">[*1236]</span> 
"will in fact alleviate [those harms] to a material degree." <i>Lorillard</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. at 555</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>. "[H]istory, consensus, and 'simple common
sense,'" <i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CDL7?jcsearch=533%20U.S.%20405&amp;summary=yes#jcite">id</a>.</i> (quoting <i>Florida, Bar v. Went For It, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=515%20us%20618&amp;summary=yes#jcite">515 U.S. 618</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=515%20us%20618&amp;summary=yes#jcite">628</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=115%20supreme%20court%202371&amp;summary=yes#jcite">115 S.Ct. 2371</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CCOK?jcsearch=132%20l%20ed%202d%20541&amp;summary=yes#jcite">132 L.Ed.2d 541</a> (1995)), demonstrate as well that warning
label requirement meets the fourth prong of the <i>Central Hudson</i> test. The
failures of previous government efforts to convey the relevant information
through small, textual warnings on the side of cigarette packages, <i>see<span CLASS="page_no" data-cite="2012 bl 217700 p 29" data-cite-type="Bloomberg" data-cite-pageno="29" data-primary-citation="">[***29]</span> </i> Final
Rule, 76 Fed.Reg. at 36, 631-32; Proposed Rule, 75 Fed.Reg. at 69, 530-31,
similar to the alternatives the tobacco companies now suggest, <i>see</i>
Appellees' Br. at 58-59, are sufficient to show that the warning labels,
with graphic images, are "not more extensive than necessary to serve" the
government's substantial interest in <i>effectively</i> conveying that information
to consumers.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The one exception is the "<cite>1-800-QUIT-NOW</cite>" telephone number. As mentioned,
it is not designed directly to inform consumers of the health consequences
of smoking, but to assist smokers in their cessation efforts. <i>See</i> Final
Rule, 76 Fed.Reg. at 36, 681. Under <i>Central Hudson</i> intermediate scrutiny,
the government's interest in reducing smoking rates is doubtless
substantial. <i>See, e.g., Lorillard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. at 564</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>; <i>Brown &amp;</i>
<i>Williamson</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=529%20us%20120&amp;summary=yes#jcite">529 U.S. at 161</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X2TTSH?jcsearch=120%20supreme%20court%201291&amp;summary=yes#jcite">120 S.Ct. 1291</a>. There also is substantial
evidence to support the FDA's determination that the display of the
"<cite>1-800-QUIT-NOW</cite>" number will directly advance this interest. The biological
and psychological effects of nicotine "can make smoking cessation extremely
difficult," PCP Report at 62; "about 40 percent of smokers try to quit" each
year, but "95 percent of those who try to quit on their own relapse," Final
Rule, 76 Fed.Reg. at 36, 681. In comparison to minimal or no counseling
interventions, quitlines have been found to "significantly increase
abstinence rates." <i></i><cite>Id. at 36</cite>, 687 (citing U.S. Dep't Health &amp; Human Servs.,
Public Health Serv., <i>Treating Tobacco Use and Dependence: 2008 Update</i> 91
(May 2008)); <i>see also</i> IOM Report at C-7. International experience referenced
in the rulemaking, <i>see</i> Final Rule, 76 Fed.Reg. at 36, 682, further supports
the common sense proposition that informing smokers of cessation resources
is likely to increase rates of successful quit attempts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  But the additional inclusion of the "1-800-QUIT-NOW" number on the warning
labels does not meet the fourth prong of <i>Central Hudson.</i> The number is
prominently presented in imperative terms, directing consumers to "QUIT
NOW." That command directly contradicts the tobacco companies' desired
message at the point of sale, thereby imposing a significant burden on their
protected commercial speech. "In previous cases addressing [the] final prong
of the <i>Central Hudson</i> test," the Supreme Court has "made clear that if the
Government could achieve its interests in a manner that does not restrict
speech, or that restricts less speech, the Government must do so." <i>Thompson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 371</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>. Unlike the warning label requirement
imposed pursuant to <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XEHFSU003?jcsearch=15%20U.S.C.%20%201333&amp;summary=yes#jcite">Section 201</a> in response to the demonstrated failures of
previously attempted, less burden-some warning requirements, the inclusion
of the "<cite>1-800-QUIT-NOW</cite>" number follows upon no apparent consideration of the
effectiveness of alternative means of connecting smokers to cessation
resources, such as a package insert.<a HREF="#fn1101" name="fnref_fn1101">[fn11]</a> Absent an explanation why such
alternatives would
<span CLASS="page_no" data-cite="402 us appeals dc 470" data-cite-type="SecondaryFederalReporter" data-cite-pageno="470" data-primary-citation="402 U.S. App. D.C. 438">[**470]</span> <span CLASS="page_no" data-cite="696 f 3d 1237" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1237" data-primary-citation="696 F.3d 1205">[*1237]</span> 
be inadequate, the government has failed to show the requisite "reasonable
fit," <i>Lorillard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. at 561</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>. <i>See Thompson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. at 373</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>.<a HREF="#fn1201" name="fnref_fn1201">[fn12]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>IV.</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, it bears noting that the court's understanding of the precedent
governing the appropriate level of scrutiny, as well as its dismissal of a
well established and substantial government interest, is inconsistent with
the Supreme <span CLASS="page_no" data-cite="2012 bl 217700 p 30" data-cite-type="Bloomberg" data-cite-pageno="30" data-primary-citation="">[***30]</span> Court's "principal" justification for "extend[ing] . . . <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a>
Amendment protection to commercial speech" &mdash; "the value to consumers of the
information such speech provides." <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=477%20us%20626&amp;summary=yes#jcite">477 U.S. at 651</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>. The Supreme Court has reiterated this justification in the
tobacco context. Addressing "substantial" restrictions on tobacco
advertising imposed by Massachusetts, the Court identified as the
"countervailing <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment interests" the tobacco companies' "interest
in conveying truthful information about their products to adults" and
adults' "corresponding interest in receiving truthful information about
tobacco products." <i>Lorillard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=533%20us%20525&amp;summary=yes#jcite">533 U.S. at 564</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X6CB47?jcsearch=121%20supreme%20court%202404&amp;summary=yes#jcite">121 S.Ct. 2404</a>. In view of
this justification, the Court has treated disclosure requirements "as
constitutionally preferable to outright suppression." <i>Pearson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X3M3MP?jcsearch=164%20f%203d%20650&amp;summary=yes#jcite">164 F.3d at 657</a> (citing recent cases). Here, the government has required the
tobacco companies not only to state, but also to show, the significant
negative health consequences of using their product as intended. The court
identifies no principled distinction, for purposes of determining the
applicable level of scrutiny, between the stating and the showing of such
information. In view of the record evidence &mdash; as well as experience and
common sense &mdash; supporting the communicative power of graphic images
accompanying textual warnings, no such distinction appears to exist.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Given the evidence demonstrating the tenacity of nicotine addiction, the
young age at which the vast majority of smokers begin smoking cigarettes,
these smokers' "incomplete understanding of the addictive nature of tobacco
use that is related, in part, to their inaccurate assessment of smoking
risks and their belief that they can quit at any time and therefore avoid
addiction," IOM Report at 89, and the significant negative health
consequences of smoking, the government has an interest of paramount
importance in effectively conveying information about the health risks of
smoking to adolescent would-be smokers and other consumers. The tobacco
companies' decades of deception regarding these risks, especially the risk
of addiction, buttress this interest. Contrary to their arguments, nothing
in the Supreme Court's commercial speech precedent would restrict the
government to conveying these risks in ways that have already proved
ineffective or would prohibit the government from employing the
communication tools tobacco companies have wielded to great effect over the
years.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For these reasons, the district court erred in applying strict scrutiny in
sustaining the tobacco companies' asapplied <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment challenge to the
Tobacco Control Act and the Final Rule, and in issuing a permanent
injunction. Because the warning label requirement (absent the
"1-800-QUIT-NOW" number) appears to survive the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment challenge
<span CLASS="page_no" data-cite="696 f 3d 1238" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1238" data-primary-citation="696 F.3d 1205">[*1238]</span> 
<span CLASS="page_no" data-cite="402 us appeals dc 471" data-cite-type="SecondaryFederalReporter" data-cite-pageno="471" data-primary-citation="402 U.S. App. D.C. 438">[**471]</span> under either <i>Zauderer</i> or <i>Central Hudson</i>, I would reverse. It would remain
for the district court on remand to address the tobacco companies'
challenges under the Administrative Procedure Act, <i>see <cite>supra</cite></i> note 1.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn101" name="fn101">[fn1]</a></span> In the district court, the tobacco companies sought injunctive relief
and challenged the label warning requirement under the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment and
the Administrative Procedure Act ("APA"). The district court granted
injunctive relief and summary judgment upon applying strict scrutiny and
ruling that the warning label requirement violated the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment. The
district court did not reach the APA claims. <i>See R.J. Reynolds Tobacco Co.</i>
<i>v. FDA.</i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=845%20f%20supp%202d%20266&amp;summary=yes#jcite">845 F.Supp.2d 266</a> (D.D.C.2012).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn201" name="fn201">[fn2]</a></span> "WARNING" precedes each of the textual statements, which consist of
the following: "Cigarettes are addictive"; "Tobacco smoke can harm your
children"; "Cigarettes cause fatal lung disease"; "Cigarettes cause cancer";
"Cigarettes cause strokes and heart disease"; "Smoking during pregnancy can
harm your baby"; "Smoking can kill you"; and "Tobacco smoke causes fatal
lung disease in nonsmokers." Tobacco Control Act &sect; 201, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=15%20usc%201333&amp;summary=yes#jcite">15 U.S.C. &sect; 1333</a>
Note.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn301" name="fn301">[fn3]</a></span> Congress contemplated that the selection of the graphic images would
be made by the FDA in view of its "scientific expertise . . . to evaluate
the impact of labels, labeling, and advertising on consumer behavior in
order to reduce the risk of harm and promote under-standing of the impact of
the product on health." Tobacco Control Act <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B9HB4003?jcsearch=21%20U.S.C.%20%20387(44)&amp;summary=yes#jcite">&sect; 2(44)</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=21%20usc%20387&amp;summary=yes#jcite">21 U.S.C. &sect; 387</a> Note.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn401" name="fn401">[fn4]</a></span> Notwithstanding any intimations it may have made in cases such as
<i>Sorrell v. IMS Health Inc.</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. 2653</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=180%20l%20ed%202d%20544&amp;summary=yes#jcite">180 L.Ed.2d 544</a>
(2011), the Supreme Court has continued to apply the more deferential
framework of <i>Central Hudson</i> to commercial speech restrictions. <i>See </i><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=131%20S.%20Ct.%202653&amp;summary=yes#jcite">id. at
2667-68</a>, 2672. As the court acknowledges, <i>see</i> Maj. Op. at 1217-18, it
therefore remains incumbent on this court to distinguish between commercial
and noncommercial speech for purposes of determining the degree of
protection afforded tobacco companies' speech under the <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=us%20const%20amend%20I&amp;summary=yes#jcite">First</a> Amendment and,
consequently, the level of scrutiny to apply. <i>See Philip Morris</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1142-43</a>. In any event, the Supreme Court's rationale in <i>Sorrell</i>
&mdash; that "the 'fear that people would make bad decisions if given truthful
information' cannot justify content-based burdens on speech," <i>Sorrell</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FK52Q003?jcsearch=131%20supreme%20court%202653&amp;summary=yes#jcite">131 S.Ct. at 2670-71</a> (quoting <i>Thompson v. W. States Med. Ctr.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">535 U.S. 357</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=535%20us%20357&amp;summary=yes#jcite">374</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=122%20supreme%20court%201497&amp;summary=yes#jcite">122 S.Ct. 1497</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/XG4UTQ?jcsearch=152%20l%20ed%202d%20563&amp;summary=yes#jcite">152 L.Ed.2d 563</a> (2002)) &mdash; does not apply here, where it
is the tobacco companies that seek to suppress truthful information.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn501" name="fn501">[fn5]</a></span> The tobacco companies advance no argument that their cigarette
packaging and advertisements propose anything other than a commercial
transaction. Nor could they, in part because of this court's determination
that tobacco companies' attempts to persuade the public to purchase
cigarettes, even in formats that did not explicitly propose a commercial
transaction, constituted commercial speech. <i>See Philip Morris</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1143-44</a>. Instead, the tobacco companies maintain that the
character of the warning labels themselves triggers the application of
strict scrutiny. <i>See</i> Appellees' Br. at 35-36. Turning the premise of the
Supreme Court's holding in <i>Zauderer</i> on its head, they assert that "attempts
to regulate 'what shall be orthodox in . . . matters of opinion' &mdash; <i>i.e.</i>,
whether individuals should buy and use a lawful product &mdash; must be subject to
strict scrutiny." Appellees' Br. at 31 (quoting <i>Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>). To the contrary, because matters of opinion over whether
individuals should buy and use a lawful product fall squarely within the
domain of commercial advertising recognized by the Supreme Court, the
regulation thereof is not, as the district court ruled, subject to strict
scrutiny. <i>See Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 651</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>Central Hudson</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9P3?jcsearch=441%20us%20562&amp;summary=yes#jcite">441 U.S. at 562</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=100%20supreme%20court%202343&amp;summary=yes#jcite">100 S.Ct. 2343</a>; <i>Philip Morris</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1142-44</a>. For
this reason, the court's invocation of noncommercial compelled speech cases
like <i>Wooley v. Maynard</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9B5?jcsearch=430%20us%20705&amp;summary=yes#jcite">430 U.S. 705</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=97%20supreme%20court%201428&amp;summary=yes#jcite">97 S.Ct. 1428</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C9B5?jcsearch=51%20l%20ed%202d%20752&amp;summary=yes#jcite">51 L.Ed.2d 752</a> (1977),
<i>West Virginia State Board of Education v. Barnette</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C0JV?jcsearch=319%20us%20624&amp;summary=yes#jcite">319 U.S. 624</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5C0JV?jcsearch=63%20supreme%20court%201178&amp;summary=yes#jcite">63 S.Ct. 1178</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=87%20l%20ed%201628&amp;summary=yes#jcite">87 L.Ed. 1628</a> (1943), and <i>Pacific Gas &amp; Electric Co. v.</i>
<i>Public Utilities Commission of California</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=475%20us%201&amp;summary=yes#jcite">475 U.S. 1</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=106%20supreme%20court%20903&amp;summary=yes#jcite">106 S.Ct. 903</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB89?jcsearch=89%20l%20ed%202d%201&amp;summary=yes#jcite">89 L.Ed.2d 1</a> (1986), <i>see</i> Maj. Op. at 1210-11, is unavailing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn601" name="fn601">[fn6]</a></span> As other circuits have recognized, in <i>Zauderer</i> the Supreme Court
appears simply to have held that a government interest in protecting
consumers from possible deception is <i>sufficient</i> to support a disclosure
requirement &mdash; not that this particular interest is <i>necessary</i> to support such
a requirement. <i>See Zauderer</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X5CB41?jcsearch=471%20us%20626&amp;summary=yes#jcite">471 U.S. at 650-51</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=105%20supreme%20court%202265&amp;summary=yes#jcite">105 S.Ct. 2265</a>; <i>Discount</i>
<i>Tobacco City &amp; Lottery v. United States</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">674 F.3d 509</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1HB3F6003?jcsearch=674%20f%203d%20509&amp;summary=yes#jcite">556</a> (6th Cir.2012);
<i>N.Y. State Rest. Ass'n v. N.Y. City Bd. of Health</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AITEQ003?jcsearch=556%20f%203d%20114&amp;summary=yes#jcite">556 F.3d 114</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1AITEQ003?jcsearch=556%20f%203d%20114&amp;summary=yes#jcite">133</a> &amp; n. 21
(2d Cir.2009); <i>Pharm. Care Mgmt. Ass'n v. Rowe</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X13HQP6003?jcsearch=429%20f%203d%20294&amp;summary=yes#jcite">429 F.3d 294</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X13HQP6003?jcsearch=429%20f%203d%20294&amp;summary=yes#jcite">310</a> n. 8 (1st
Cir.2005); <i>Nat'l Elec. Mfrs. Ass'n v. Sorrell</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X51DFS?jcsearch=272%20f%203d%20104&amp;summary=yes#jcite">272 F.3d 104</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X51DFS?jcsearch=272%20f%203d%20104&amp;summary=yes#jcite">115</a> (2d
Cir.2001). In view of the likelihood of consumer confusion or deception
shown here, there is no need to determine whether the scope of <i>Zauderer</i>
encompasses other government interests.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn701" name="fn701">[fn7]</a></span> The court attempts to distinguish <i>Warner-Lambert</i> on the ground that
the FDA "does not frame <i>this</i> rule as a remedial measure designed to
counteract specific deceptive claims made by the Companies." Maj. Op. at
1215. Even if <i>Warner-Lambert's</i> reasoning were limited to remedial measures,
surely Congress could provide the requisite "framing." Especially in view of
the high level of specificity with which Congress crafted the warning label
requirement, it was not incumbent upon the FDA to supplement the
congressional findings already supporting the requirement. Nonetheless, the
FDA <i>did</i> frame its rule as a measure designed to counteract specific gaps in
consumers' knowledge of the health risks of smoking, <i>see</i> Final Rule,
76 Fed.Reg. at 36, 632-33 &mdash; gaps that align with specific deceptive claims
made by the tobacco companies, <i>see Philip Morris</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">566 F.3d at 1106-07</a>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1B54NK003?jcsearch=566%20f%203d%201095&amp;summary=yes#jcite">1118-19</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn801" name="fn801">[fn8]</a></span> Indeed, in addressing a RICO injunction, this court recently
acknowledged the "reasonable likelihood" &mdash; notwithstanding the restrictions
imposed in the Tobacco Control Act &mdash; that the tobacco companies would commit
future RICO violations, <i>United States v. Philip Morris USA Inc.</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=686%20f%203d%20832&amp;summary=yes#jcite">686 F.3d 832</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=686%20f%203d%20832&amp;summary=yes#jcite">837</a> (D.C.Cir.2012), where their past RICO violations consisted
of proven "misstatements and acts of concealment and deception . . . made
intentionally and deliberately . . . as part of a multifaceted,
sophisticated scheme to defraud," <i>id.</i> at 834; <i>see United States v. Philip</i>
<i>Morris USA, Inc.</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FHCGA003?jcsearch=787%20f%20supp%202d%2068&amp;summary=yes#jcite">787 F.Supp.2d 68</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FHCGA003?jcsearch=787%20f%20supp%202d%2068&amp;summary=yes#jcite">74-75</a> (D.D.C.2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn901" name="fn901">[fn9]</a></span> The district court relied on <i>Entertainment Software Association v.</i>
<i>Blagojevich</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X160QP2003?jcsearch=469%20f%203d%20641&amp;summary=yes#jcite">469 F.3d 641</a> (7th Cir.2006), for the proposition that label
requirements "ultimately communicat[ing] a subjective and highly
controversial message" fall outside the scope of "purely factual and
uncontroversial" disclosures permitted under <i>Zauderer. R.J. Reynolds</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1Q6M5KN5I82?jcsearch=845%20f%20supp%202d%20266&amp;summary=yes#jcite">845 F.Supp.2d at 274</a> (quoting <i>Blagojevich</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X160QP2003?jcsearch=469%20f%203d%20641&amp;summary=yes#jcite">469 F.3d at 652</a>) (internal
quotation marks omitted). But <i>Blagojevich</i> involved labels that were
necessarily subjective and exclusively nonfactual. As the Supreme Court
later explained, because video games "communicate ideas &mdash; and even social
messages," they enjoy full <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/1?citation=USCONST%20Amend.%20I&amp;summary=yes#jcite">First</a> Amendment protection, which guards against
government efforts "to restrict expression because of its message, its
ideas, its subject matter, or its content." <i>Brown v. Entm't Merchs. Ass'n</i>,
<cite>___ U.S. ___</cite>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FKH0E003?jcsearch=131%20supreme%20court%202729&amp;summary=yes#jcite">131 S.Ct. 2729</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FKH0E003?jcsearch=131%20supreme%20court%202729&amp;summary=yes#jcite">2733</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1FKH0E003?jcsearch=180%20l%20ed%202d%20708&amp;summary=yes#jcite">180 L.Ed.2d 708</a> (2011) (citation and
internal quotation marks omitted). The labels at issue in <i>Blagojevich</i>
represented exactly such an effort: the challenged provision required the
label to be placed on games deemed "sexually explicit," the state's
definition of which was "far more opinion-based than the question of whether
a particular chemical is within any given product." <i>Blagojevich</i>,
<a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X160QP2003?jcsearch=469%20f%203d%20641&amp;summary=yes#jcite">469 F.3d at 652</a>. These labels were nonfactual because there were no facts to
convey.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1001" name="fn1001">[fn10]</a></span> <i>See also</i> <cite>155 CONG. REC. S6021</cite> (daily ed. June 3, 2009) (statement of
Sen. Lautenberg) (sharing testimony of woman who, "despite the fact that she
had essentially lost her voice box, . . . still smoked through the hole in
her throat," and explaining that "[t]he hold on people is almost
unbreakable").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1101" name="fn1101">[fn11]</a></span> <i>See, e.g.</i>, Appellants' Reply Br. at 30(citing cessation resource
information displayed on the websites of one tobacco company,
http://www.lorillard.com/?s=quit + smoking and the subsidiary of another,
http://www.sfntc.com/Quit-Smoking/Overview.aspx).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1201" name="fn1201">[fn12]</a></span> Neither the tobacco companies nor the rulemaking record suggests that
the FDA would not have promulgated the Final Rule had the "<cite>1-800-QUIT-NOW</cite>"
number been struck from the warning labels, and it can be severed. <i>See North</i>
<i>Carolina v. EPA</i>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X197O6I003?jcsearch=531%20f%203d%20896&amp;summary=yes#jcite">531 F.3d 896</a>, <a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X197O6I003?jcsearch=531%20f%203d%20896&amp;summary=yes#jcite">929</a> (D.C.Cir.2008).
</p></div>
<!--BBLS DD 1723411202051-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I51L0003/history">Direct History (4)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I51L0003/analysis">Case Analysis (8)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I51L0003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
8
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Injunction Vacated, Case Remanded, Judgment Affirmed (In Part), Judgment Vacated (In Part)</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Tobacco</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1Q6M2VKFF82">11-05332 (D.C. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/d7074db4db9ad4e305df80d1335feb34/document/X1Q6M5OLQ7O2">12-05063 (D.C. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Consumer Law</div><div class='facetItemLabel'>Government</div><div class='facetItemLabel'>Health Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/d7074db4db9ad4e305df80d1335feb34/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "d7074db4db9ad4e305df80d1335feb34";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY127f74&previousPageId=&previousActivityInstanceId=ENTITYb76c91&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:25:53-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I51L0003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYb76c91&previousPageId=&previousActivityInstanceId=ENTITY313bc3&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T07:25:45-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I51L0003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I51L0003";
$('#page_loader').show().spin();
JUDGE_IDS=["2120413"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
